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Abstract 
Our National Preparedness Vision requires the U.S. to be prepared to prevent, 
protect against, respond to, and recover from all hazards associated with a chemical 
attack.  Results of this study demonstrate that we cannot protect service members and 
first responders as required following a nerve agent attack.  The research presented herein 
aimed to construct a physiologically based pharmacokinetic model to determine optimal 
therapeutic strategies for organophosphate (nerve agent) poisoning. The constructed 
model integrated organophosphates and two antidotes, atropine and oximes. Currently, 
both antidotes are fielded to military members of all services for medical treatment.  
Model results reasonably mirrored literature data and anecdotal observations of 
organophosphate poisoning. Results suggest a symptoms-based dosing strategy of 
atropine and a time-based dosing strategy of oximes. For patients severely poisoned with 
organophosphorus nerve agents, which are to be expected in combat operations, model 
results support documented claims of oxime’s inefficacy and tendency to heighten the 
severity of poisoning.  The results strongly indicate that military personnel attacked with 
nerve agents are at a significant health risk if they employ their prescribed treatment as 
current doctrine dictates.  Results presented herein suggest that oxime use be 
discontinued as currently prescribed within the context of nerve agent exposure; its use 
will not alter the effects of nerve agent exposure and may increase adverse effects.    
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OPTIMIZATION OF THERAPEUTIC STRATEGIES FOR 
ORGANOPHOSPHATE POISONING 
 
I. Introduction 
Background 
In the 1800s, chemists synthesized the first organophosphorus chemical (Szinicz, 
2005:173). Researchers later created various forms of the organophosphate and applied 
the chemicals as insecticides (Szinicz, 2005:173). In the 1930s, a German chemist 
developed exceptionally lethal organophosphates, which were soon applied to weapon 
systems and eventually classified as the first nerve agents (Szinicz, 2005:173). Continued 
investigation of these chemicals over the past seventy years has produced greater variants 
of organophosphorus insecticides and nerve agents (Cannard, 2006:87). 
 Organophosphates poison an estimated 100,000 people each year throughout the 
world (Thiermann and others, 1999:23). The mechanism of poisoning is consistent for all 
organophosphate varieties (Szinicz and others, 2007:27). When introduced into the body, 
organophosphates bind to acetylcholine esterases at neural synapses (Cannard, 2006:86). 
The function of acetylcholine esterases is to hydrolyze neural transmitters, known as 
acetylcholine molecules (Cannard, 2006:87). Acetylcholine molecules carry neural 
transmissions across synapses from one nerve cell to another nerve cell (Cannard, 
2006:87). While acetylcholine esterases are bound to organophosphates, acetylcholine 
molecules are not hydrolyzed and are free to repeatedly stimulate the receiving nerve cell 
(Cannard, 2006:87). This continuous neural stimulation produces the classic symptoms of 
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organophosphate poisoning, which include, among many, muscle spasms and excess 
gland secretion (Cannard, 2006:88). The most severe poisonings can result in respiratory 
failure and death (Cannard, 2006:89). 
 The two widely accepted antidotes for organophosphate poisoning are atropine 
and oximes (Cannard, 2006:92). Atropine temporarily binds to neural receptor sites 
without initiating neural stimulation (Cannard, 2006:92). Atropine’s competition for the 
neural receptor sites reduces acetylcholine molecules’ access to these sites and, 
subsequently, dampens excessive neural stimulation (Cannard, 2006:92). Oximes break 
organophosphate-acetylcholine esterase bonds (Cannard, 2006:92). Freed acetylcholine 
esterases may then resume the hydrolysis of acetylcholine molecules and, consequently, 
also dampen excessive neural stimulation (Cannard, 2006:92). 
 Despite the wide acceptance of these antidotes to mitigate organophosphate 
poisoning, various government agencies currently suggest different dosing strategies for 
the antidotes (Cannard, 2006:91). Some researchers acknowledge that the optimal dose of 
the antidotes is controversial (Heath and McKeown, 2002:24). The conflicting treatment 
strategies result from a deficiency in the overall organophosphate research. This research 
deficiency has inspired the purpose of this thesis.  
Research Objectives 
1. Construct a physiologically based pharmacokinetic (PBPK) model to predict the 
tissue concentrations of organophosphates, atropine, oximes, and pertinent 
biological chemicals. 
2. Integrate the reactions among these chemicals into the model and produce a 
quantitative measurement of their aggregate effects. 
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3. Apply therapeutic strategies for atropine and oximes against an organophosphate 
exposure to the model. 
4. Compare model output and report significant differences in therapeutic strategies. 
Challenges 
 Over the past fifteen years, a few researchers have applied PBPK modeling to 
predict levels of organophosphates in human tissue. In 1994, Gearhart and others created 
the first such PBPK model for two types of organophosphates (Gearhart and others, 
1994:1). The researchers provided evidence that a PBPK model for organophosphates 
could be adapted for cross-species studies and across the family of organophosphorus 
chemicals (Gearhart and others, 1994:12-13). In 2002, Timchalk and others supported 
these findings with a similar study on a different organophosphate (Timchalk and others, 
2002:42). Also in 2002, Gentry and others conducted a similar study, but the researchers 
expanded the utility of the PBPK model to incorporate greater interaction between the 
organophosphates and biological chemicals (Gentry and others, 2002:137). However, 
none of these studies have fully incorporated the antidotes and their interactions with 
other chemicals into the model across all tissue groups. As a result, the proposed research 
will require an expansion of the scope and utility of the models presented in literature.  
 Research literature provides limited information on model parameters and 
coefficients for organophosphates and their antidotes. The toxic nature of the chemicals 
makes human testing difficult and, in some cases, impossible. In addition, Szinicz and 
others suggest that pharmaceutical companies have little motivation to invest in more 
detailed research concerning organophosphate poisoning (Szinicz and others, 2007:23-
24). Therefore, this research must determine some parameters and coefficients that 
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produce model results, which mimic limited observations of organophosphate poisoning 
and antidote efficacy.   
 Furthermore, some researchers question the efficacy of oximes. Animal and in 
vitro experiments suggest that oximes are effective, while other reports of 
organophosphate poisoned humans suggest oximes are ineffective (Szinicz and others, 
2007:25). Szinicz and others acknowledge that “the true efficacy of oximes in patients 
with acute organophosphate poisoning is not known” (Szinicz and others, 2007:25). The 
researchers suggest that future studies on oximes consider the possibility that 
acetylcholine esterases, freed from bonds with organophosphates by oximes, rebind with 
“persisting organophosphates in the body” (Szinicz and others, 2007:26). 
Finally, the deleterious effects of organophosphate poisoning are numerous, and 
the severity of organophosphate poisoning varies across the chemical class (Cannard, 
2006:88-89). In addition, the effectiveness of an antidote dose varies with the severity of 
organophosphate toxicity (Cannard, 2006:91). This study must aggregate the reactions 
among organophosphates, antidotes, and biological chemicals to produce a single, 
quantifiable result in order to facilitate comparison among different therapeutic strategies. 
Justification and Applicability 
Organophosphorus insecticides are one of the most predominant insecticides used 
today (Reigart and Roberts, 1999:34). Over forty registered brands of insecticides contain 
organophosphorus chemicals (Reigart and Roberts, 1999:34). In 1996, the United States 
accounted for more than 4,000 of the yearly organophosphate poisonings experienced 
throughout the world (Reigart and Roberts, 1999:5). Since relatively minor poisonings do 
not necessarily initiate medical treatment, these numbers are likely an underestimate of 
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actual organophosphate poisonings. Most organophosphate poisonings occur through 
association with the agricultural industry by accidental and excessive exposure or by 
improper application of insecticides (Calvert and others, 2004:20). 
Sarin, soman, tabun, and VX are the most common nerve agents (Cannard, 
2006:87). Despite being first developed in the 1930s, it was not until the 1980s, well after 
international bodies established protocols to curb use of these chemicals, that the first 
employment of nerve agents as a weapon was documented (Szinicz, 2005:172). Iraq 
employed tabun and sarin against Iranian military forces between 1983 and 1984 and 
between 1987 and 1988 during the Iran-Iraq War (Szinicz, 2005:172). Iraq also employed 
sarin against civilian Iraqi Kurds, an ethnic sub-population of Iraq, between 1987 and 
1988 (Szinicz, 2005:172). 
In 1994, Aum Supreme Truth, a religious cult, synthesized sarin and employed 
the chemical against Japanese government agencies and citizens to further the cult’s 
political and religious goals (Yanagisawa and others, 2006:76). The terrorist cult released 
12 liters of a 70% sarin solution in Matsumoto, Japan (Yanagisawa and others, 2006:77). 
The nerve agent killed 7 people and caused 56 hospital inpatient casualties, 208 hospital 
outpatient casualties, and 277 on-scene treated sicknesses (Yanagisawa and others, 
2006:77). In 1995, the terrorist group again released sarin, this time on the Tokyo 
subway, killing 12 people and causing over 500 illnesses, which included 100 first care 
responders. (Yanagisawa and others, 2006:81)   
The history of organophosphates is disturbing. Despite growing knowledge of the 
toxicity of these chemicals and government controls and education efforts to reduce 
poisonings, the use of these chemicals and number of annual poisonings remains 
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significantly high. In addition, despite international efforts to control the development, 
storage, proliferation, and use of nerve agents, it has not been enough to deter 
governments and terrorist organizations from creating and employing these chemicals.  
The threat of organophosphate poisoning is genuine and current. A more complete 
understanding of organophosphate antidotes could help to more effectively mitigate 
symptoms and save lives. The rapid onset of organophosphate induced symptoms and the 
chemicals’ potential to quickly cause death, especially from the more toxic 
organophosphates, provides motivation to more accurately and decisively define the 
dosing strategies for prompt and proper treatment. 
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II. Literature Review 
History of Methodology 
Since the development of organophosphates, researchers have conducted much 
study to better understand the chemicals. In the late 1980s, a subset of the overall 
organophosphate research arose that involves the application of physiologically based 
pharmacokinetic (PBPK) modeling (Maxwell and others, 1987:66). PBPK models predict 
tissue dose concentrations of chemicals in organisms with respect to time (Andersen, 
2003:10). The model categorizes human mass into discrete tissue groups with similar 
pharmacokinetic properties (Andersen, 2003:12). Modelers create mass balance 
differential equations around each tissue group (Andersen, 2003:11). Equation 
parameters include tissue volumes, blood flow rate, breathing rate, metabolic constants, 
and unique chemical characteristics (Andersen, 2003:12). The modeling tool numerically 
integrates the equations to determine the chemical amounts in the tissue over time 
(Andersen, 2003:11).  
 PBPK modeling is predominantly used to predict human tissue concentrations of 
a chemical by inferring data from laboratory experiments conducted on animals 
(Andersen, 2003:13-14). In general, this method gains data from test animals, applies the 
data to a PBPK model, adjusts the model to simulate experimental results, and then 
applies human parameters to the model in place of animal parameters to predict human 
results (Andersen, 2003:13-14). Modelers then repeatedly execute the human model over 
a wide range of scenarios that were not studied in the laboratory experiment (Andersen, 
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2003:10). Not only does this technique save time and money, but it also allows 
researchers to obtain human results when human experiments are impossible or severely 
limited due to the toxicity of the chemical (Andersen, 2003:14). In addition, the modeling 
technique allows researchers to obtain results for humans exposed to low dose 
concentrations of a chemical over decades from data obtained through laboratory 
experiments on animals exposed to high dose concentrations of a chemical over days or 
weeks (Andersen, 2003:10). 
 Another valuable application of PBPK modeling is to create a hypothesis for a 
future laboratory experiment based on the results of the model, which was created from 
the current understanding of physiology and the chemicals under study (Andersen, 
2003:14). This technique is particularly useful when physiological mechanisms and 
chemical interactions are vaguely understood or are unproved and when historical data 
are limited. A successful model will predict future results of laboratory experiments and 
help provide evidence to support understood mechanisms (Andersen, 2003:14). However, 
and ironically, an unsuccessful model, which fails to predict future laboratory results, is 
likely more useful in that it initiates rigorous questioning of understood mechanisms. 
This rigorous questioning may lead to insights and greater understanding of a chemical 
and its interactions with physiology (Andersen, 2003:14). 
The application of PBPK modeling for organophosphates began in 1988 with a 
study by Maxwell and others (Maxwell and others, 1988:66). The researchers dosed rats 
with 90 μg/kg of soman and measured tissue concentrations of the organophosphate and 
acetylcholine esterase inhibition (Maxwell and others, 1988:68). These measurements 
were used to determine any correlation among the organophosphate tissue concentration, 
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esterase inhibition, and physiological parameters (Maxwell and others, 1988:67). 
Maxwell and others found a strong correlation between esterase inhibition and blood 
flow, a key component of PBPK modeling (Maxwell and others, 1988:69-72). As a 
result, the researchers suggested “that it may be possible to use a flow-limited 
physiological pharmacokinetic model to describe the kinetics of in vivo esterase 
inhibition by soman” (Maxwell and others, 1988:66). 
In 1994, Gearhart and others tested Maxwell’s suggestion. The researchers 
determined “to develop a quantitative, physiologically based model for organophosphate 
pharmacokinetics and acetylcholine esterase inhibition” (Gearhart and others, 1994:3). 
The researchers dosed rats with the organophosphate, diisopropylfluorophosphate (DFP), 
and measured tissue concentrations of the organophosphate and esterase activity 
(Gearhart and others, 1994:5). The researchers then constructed a model and optimized 
parameters until the model simulated the experimental data (Gearhart and others, 1994:5-
6). Next, the researchers applied human parameters to the model (Gearhart and others, 
1994:5-6). Model results for the human reasonably mirrored DFP data obtained from 
literature concerning DFP therapeutic treatments (Gearhart and others, 1994:13). 
Furthermore, the researchers then adapted the model to another organophosphate, 
parathion (Gearhart and others, 1994:13). Again, the model results reasonably mirrored 
literature data (Gearhart and others, 1994:13). The researchers provided evidence that the 
PBPK model could predict tissue concentrations of organophosphates, that the model was 
applicable for cross-species studies, and that the model was applicable across the family 
of organophosphorus chemicals (Gearhart and others, 1994:12-13).  
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In 2002, Timchalk and others created a similar PBPK model for chlorpyrifos 
(CFP), a less lethal organophosphate, which is used in insecticides (Timchalk and others, 
2002:34). The researchers fed rats with CFP and measured tissue concentrations of CFP 
over time (Timchalk and others, 2002:35). Using the experimental data, literature data, 
and optimization techniques, the researchers successfully constructed a model that 
produced results that mirrored the experiment (Timchalk and others, 2002:35). The 
researchers then applied human parameters to the model (Timchalk and others, 2002:41). 
As with the study by Gearhart and others, the model reasonably mirrored experimental 
data obtained from human testing from another study (Timchalk and others, 2002:42). 
Again, more evidence supported PBPK modeling of organophosphates (Timchalk and 
others, 2002:42). 
In 2002, Gentry and others created a similar PBPK model for the 
organophosphate, parathion, and its metabolite, paraoxon (Gentry and others, 2002:120). 
The researchers intended to provide an estimate on how polymorphism affects tissue 
doses and toxicity of a chemical (Gentry and others, 2002:120). Although the results of 
the experiment showed that the genetic variations had little effect on the toxicity of 
parathion, the study did further provide evidence for applying PBPK modeling to 
determine tissue concentrations of organophosphates (Gentry and others, 2002:131). In 
addition, the researchers were able to expand the utility of the model by incorporating 
greater interaction between the organophosphate and biological chemicals (Gentry and 
others, 2002:125-137). 
PBPK modeling is highly dependent upon the mechanisms of the cardiovascular 
system. Organophosphates and their antidotes interact extensively with the nervous 
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system. To facilitate a more detailed explanation of the mechanisms of the chemicals and 
PBPK modeling, the next two sections will provide a brief review of the cardiovascular 
and nervous systems. 
Cardiovascular System 
 The cardiovascular system consists of the heart and a network of closed loop 
blood vessels (Fox, 2006:382). Arteries transport blood away from the heart and veins 
return blood to the heart (Fox, 2006:382). Capillaries are smaller and more numerous 
vessels that connect arteries and veins in tissue (Fox, 2006:406). 
 Blood consists of erythrocytes, leukocytes, and platelets, which are suspended in 
plasma (Fox, 2006:384-385). Plasma is predominantly water and solutes (Fox, 2006:383).  
 An important function of the cardiovascular system is to carry nutrients, waste, 
and other chemicals to and from tissue (Fox, 2006:382). All transfer of materials to and 
from the blood and tissue occurs across capillary walls (Fox, 2006:382-383). The human 
body consists of more than 40 billion capillaries that provide nearly 1000 square miles of 
surface area for diffusion of chemicals between blood and tissue (Fox, 2006:408). Nearly 
every cell in the human body is within 60 to 80 μm of a capillary (Fox, 2006:408). 
Blood pressure drives water and solutes from the plasma through capillary walls 
into interstitial fluid at the arterial end of capillaries (Fox, 2006:431). As blood pressure 
drops at the venous end of the capillaries, concentration gradients will drive some 
amounts of water and solutes from the interstitial fluid back into the capillaries (Fox, 
2006:432). 
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Figure 1. Capillary Diffusion (Fox, 2006:431-432) 
Nervous System 
 Motor neurons are classified as somatic or autonomic (Fox, 2006:156).  Somatic 
motor neurons direct the reflexive and voluntary control of skeletal muscles (Fox, 
2006:156).  Originating in the central nervous system (CNS), somatic neurons extend into 
the peripheral nervous system (PNS) and terminate at receptors of skeletal muscles (Fox, 
2006:156). Autonomic motor neurons are located in the PNS (Fox, 2006:156).  
Autonomic neurons receive neural transmission from other neurons extending from the 
CNS and relay the neural transmission to receptors of involuntary tissues: smooth 
muscles, cardiac muscle, and glands (Fox, 2006:156). 
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Figure 2. Central and Peripheral Nervous System (adapted from Fox, 2006:156) 
An approximately 10 nm wide cleft, called a synapse, separates neurons from 
other neurons, muscles, and glands (Fox, 2006:172).  Adhesion molecules that project 
from both sides of the synapse hold the width of the cleft constant. (Fox, 2006:171)  
Neural transmission across synapses of motor neurons is one-way, in the direction from 
the CNS to the receptor, and occurs with the release of neurotransmitters from the pre-
synaptic neuron and the reception of neurotransmitters by the post-synaptic cell (Fox, 
2006:172).  Acetylcholine molecules are the most common neurotransmitters in the body 
and the ones indirectly affected by organophosphate poisoning (Fox, 2006:175). 
The pre-synaptic neuron contains small sacs, which store acetylcholine molecules 
(Fox, 2006:172).  Upon neural stimulation, the sacs fuse with the membrane of the pre-
synaptic neuron and create pores through which the acetylcholine molecules diffuse into 
the synaptic cleft (Fox, 2006:172).  The amount of acetylcholine molecules released into 
the cleft is dependent on the amount of acetylcholine molecules in the sac, the number of 
sacs fusing to the membrane, and the frequency of neural transmission (Fox, 2006:172).  
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Some of the sacs are pre-staged at the pre-synaptic nerve cell membrane to increase the 
speed of neural transmission (Fox, 2006:172).  
Figure 3. Acetylcholine Structure (Rand, 2007:116) 
Once in the cleft, acetylcholine molecules diffuse across the synapse through 
interstitial fluid and briefly bind to receptor sites on the post-synaptic cell (Fox, 
2006:173-177).  It is these binds between acetylcholine molecules and the post-synaptic 
receptor sites that stimulate the neural functioning of the post-synaptic cell (Fox, 
2006:173).  After a short time, acetylcholine molecules will disassociate from the 
receptor sites and maintain the potential to re-bind to the receptors (Fox, 2006:177). 
There are two types of cholinergic receptors that receive acetylcholine molecules: 
nicotinic receptors and muscarinic receptors (Fox, 2006:174-175). Nicotinic receptors are 
found between neurons and skeletal muscles, between neurons and non-voluntary 
muscles, and between some neurons and other neurons in the CNS (Fox, 2006:174).  
Muscarinic receptors are found between neurons and glands in the PNS and also between 
some neurons and other neurons in the CNS. (Fox, 2006:175) 
 Acetylcholine esterases are enzymes embedded on the post-synaptic cell and 
which terminate the action of acetylcholine molecules (Fox, 2006:177). The serine 
hydroxyl group of the acetylcholine esterase binds to the acetyl portion of the 
acetylcholine. With this bind, the choline moiety of the acetylcholine is released 
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(Cannard, 2006:87). Hydrolysis then separates the acetyl moiety from the acetylcholine 
esterase (Cannard, 2006:87). The choline moiety will return to the pre-synaptic cell to be 
recycled for the creation of new acetylcholine, while the acetyl group will react with 
water to form acetic acid (Cannard, 2006:87). Acetylcholine esterases are extremely 
effective and each enzyme has the potential to hydrolyze 300,000 acetylcholine 
molecules per minute (Hoskins and Ho, 1992:289). Acetylcholine esterases are the only 
enzymes that hydrolyze acetylcholine. Without acetylcholine esterases, acetylcholine 
molecules will persist in the synaptic cleft, continually bind and disassociate with 
receptor sites, and cause excessive neural stimulation (Fox, 2006:178).   
Figure 4. Synaptic Cleft (adapted from Fox, 2006:178) 
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Organophosphates 
Organophosphates are liquid chemicals (Cannard, 2006:87). An organophosphate 
is characterized by central phosphorous atom bound to an oxygen atom, two alkyl groups, 
and a leaving group (Cannard, 2006:87).  Although liquid, organophosphates are, 
generally, easily volatized (Cannard, 2006:87). As a result, the most likely human 
exposure to organophosphates is through inhalation, although intake of the chemicals 
through dermal absorption or ingestion is possible (Cannard, 2006:87).  
Figure 5. Organophosphate Structure (Cannard, 2006:87) 
Regardless of the entry route into the body, organophosphates will diffuse into the 
blood stream, and the cardiovascular system will transport the chemicals to all tissue 
groups. In the tissue groups, organophosphates will move towards neural synapses and 
bind to acetylcholine esterases (Cannard, 2006:87). After a period of time, which is 
different for each organophosphate type, the organophosphate-esterase bonds will mature 
by the de-alkylation of the organophosphates (Cannard, 2006:87). Upon maturation, the 
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organophosphate-esterase bonds will become irreversible and both the organophosphates 
and acetylcholine esterases are destroyed. (Cannard, 2006:87)     
When acetylcholine esterases are bound to organophosphates, acetylcholine 
molecules are not hydrolyzed, accumulate in the synapse, and cause over-stimulation of 
the nervous system (Cannard, 2006:87).  This over-stimulation leads to a variety of 
physiological effects, which are dependent on the type of neural receptor and location in 
the body (Cannard, 2006:88-89). 
In the PNS, over stimulation of muscarinic receptors causes continuous 
contraction of smooth muscles and secretion of exocrine glands (Cannard, 2006:88).  
Effects include “miosis with dim or blurred vision, eye pain (ciliary spasm) or headache, 
tearing, rhinorrhea, salivation, bronchoconstriction and excessive bronchosecretions with 
dyspnea, bradyarrhythmias, hypotension, nausea and vomiting, abdominal cramps, 
diarrhea and bowel incontinence, and urinary incontinence” (Cannard, 2006:88). Also in 
the PNS, organophosphates lead to the over-stimulation of nicotinic receptors causing 
uncontrolled contraction of voluntary muscles (Cannard, 2006:87). 
Both muscarinic and nicotinic receptors are found in the CNS (Fox, 2006:156).  
In the CNS, over-stimulation of both receptor types causes “mild to severe behavioral and 
cognitive changes, impaired consciousness or coma, seizures, or central apnea” (Cannard, 
2006:89).  If the exposed person survives the initial effects of organophosphate 
poisoning, other symptoms may persist for weeks and include “irritability, anxiety, 
depression, fatigue, insomnia, nightmares, and impaired judgment” (Cannard, 2006:89). 
The only way to terminate the effects of organophosphate poisoning is the 
elimination of the organophosphates from the body and the full recovery of acetylcholine 
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esterases (Cannard, 2006:87). Destruction of the organophosphates is relatively quick via 
natural metabolic degradation. However, the recovery of acetylcholine esterases is 
relatively slow (Cannard, 2006:87).  Effects from organophosphate poisoning can persist 
for weeks as a result of deficient acetylcholine esterases in tissue groups and not from 
organophosphate persistence in the body (Cannard, 2006:89). 
Four naturally occurring chemicals in the body will destroy organophosphates 
(Gearhart and others, 1994:4). At the neural synapse, acetylcholine esterases initiate the 
release of the organophosphates’ leaving group and the destruction of the 
organophosphates upon bond maturation (Cannard, 2006:87).  
In addition to being found in tissue groups, butyrylcholinesterases and other 
acetylcholine esterases are found in the blood stream and have the first opportunity to 
attach to organophosphates (Cannard, 2006:86). Like organophosphate-acetylcholine 
esterase bonds, organophosphate-butyrylcholinesterase bonds become irreversible with 
maturation, and the butyrylcholinesterases and organophosphates are destroyed with the 
separation of the organophosphates’ leaving group (Gearhart and others, 1994:4).  Unlike 
acetylcholine esterases, the loss of butyrylcholinesterases to organophosphate poisoning 
appears to have no imminent effect on life sustaining functions (Cannard, 2006:88). 
Carboxylesterases are found throughout the body and in much greater numbers 
than acetylcholine esterases and butyrylcholinesterases. These enzymes also bind to and 
mature with organophosphates (Gearhart and others, 1994:4). As with 
butyrylcholinesterases, there is no known adverse physiological affect from the loss of 
carboxylesterases. 
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The enzyme suite, cytochrome P450, metabolizes organophosphates. (Levi and 
Hodgson, 1992:142).  Elements of this enzyme suite are found in all tissue groups except 
fat tissue (Gearhart and others, 1994:3). 
Antidotes 
There are three widely accepted medications to treat organophosphate poisoning. 
The first medication, oxime, is introduced into the body intravenously or intramuscularly 
(Cannard, 2006:92).  Oximes will attack the organophosphate-esterase bonds and 
separate the chemicals (Cannard, 2006:92).  However, oximes are only effective prior to 
maturation of the organophosphate-esterase bonds (Cannard, 2006:92).  For reference, 
the maturation half-time of soman is 2-6 minutes, while the maturation half-time for 
tabun, sarin, and VX is between 5 and 48 hours (Cannard, 2006:92). Esterases are fully 
recovered and operational with effective separation from the organophosphates (Cannard, 
2006:92). However, oximes appear to “have little effect on muscarinic symptoms and 
signs” (Cannard, 2006:92). There are a few varieties of oximes, but they all operate in 
essentially the same manner (Cannard, 2006:92). The U.S. uses Pralidoxime Chloride (2-
Pam Cl) (Cannard, 2006:92). 
Atropine may also be introduced into the body intravenously or intramuscularly 
(Cannard, 2006:92).  At muscarinic receptors only, atropine will repeatedly bind to and 
dissociate with the neural receptors without causing neural stimulation (Cannard, 
2006:92).  The presence of atropine will reduce the availability of muscarinic receptors to 
acetylcholine molecules (Cannard, 2006:92).  As a result, atropine will reduce the 
excessive secretion of exocrine glands and the over-stimulation of smooth muscles 
(Cannard, 2006:92).  The body will naturally metabolize or excrete atropine over time. 
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At high doses, atropine can cause adverse health effects (USAMRICD, 
2000:120). Generally, people not exposed to organophosphates with doses of 10 mg of 
atropine or higher may experience delirium (USAMRICD, 2000:120). In addition, the 
blockage of neural receptors at glands may inhibit sweating and endanger an individual to 
heat related injuries (USAMRICD, 2000:120). Furthermore, small amounts of atropine 
can cause blurred vision for up to a day (USAMRICD, 2000:123).  
The third medication for organophosphate poisoning is an anticonvulsant, and 
diazepam is the preferred medicine (Cannard, 2006:92).  Diazepam reduces the severity 
of seizures and epilepsy, which are caused by over-stimulation of muscarinic and 
nicotinic receptors in the CNS (Cannard, 2006:92-93). This medication will not be 
studied in the model. 
Therapeutic Strategies 
Therapeutic strategies vary among government agencies (Cannard, 2006:91). The 
Centers for Disease Control and Prevention (CDC) base initial dosing procedures on 
observations of symptoms (CDC, 2008:13).  The symptoms are classified as either mild-
moderate or severe (CDC, 2008:13).  “Mild-moderate symptoms include localized 
sweating, muscle fasciculations, nausea, vomiting, weakness, and dyspnea” (CDC, 
2008:13).  For adults with these symptoms, first care responders are directed to initially 
administer one or two atropine injections of 2 mg each and one 2-Pam Cl injection of 600 
mg (CDC, 2008:13). Additional atropine doses are repeated every 5 to 10 minutes (CDC, 
2008:13). There are no instructions to first care responders for repeated doses of 2-Pam 
Cl. Both atropine and 2-Pam Cl injections are administered intramuscularly by first care 
responders (CDC, 2008:13). 
 
21 
“Severe symptoms include unconsciousness, convulsions, apnea, and flaccid 
paralysis” (CDC, 2008:13). For adults, first care responders are directed to administer 
three atropine injections of 2 mg each (CDC, 2008:13).  Additional atropine injections of 
2 mg should be administered “at 5 to 10 minute intervals until secretions have diminished 
and breathing is comfortable or airway resistance has returned to normal” (CDC, 
2008:13).  Eighteen hundred mg of 2-Pam Cl are administered with the initial atropine 
injection. (CDC, 2008:13). As with mild to moderate symptoms, there are no instructions 
for additional doses of 2-Pam Cl (CDC, 2008:13).  
Medical doctors with appropriate equipment are provided slightly different 
instructions (CDC, 2008:19). The procedure for administering atropine is identical to the 
instructions provided to first care responders (CDC, 2008:19).  However, medical doctors 
will slowly administer 15 mg/kg of 2-PAM Cl intravenously for mild-moderate and 
severe symptoms (CDC, 2008:19).  In addition, medical doctors may administer 5 mg of 
diazepam intravenously for patients with convulsions (CDC, 2008:19). 
The New York Department of Health (NYDH) provides slightly different 
procedures for first care responders (NYDH, 2008:4). For mild to moderate symptoms, 2 
to 4 mg of atropine and 600 mg of oxime are administered intramuscularly (NYDH, 
2008:4). For severe symptoms, 6 mg of atropine and 1800 mg of oxime are administered 
intramuscularly (NYDH, 2008:4). For all cases, unspecified amounts of atropine are 
repeated every 2 to 5 minutes until breathing has returned to near normal (NYDH 
2008:4). Unspecified amounts of 2-Pam Cl are repeated once between 30 to 60 minutes 
and then 1 to 2 doses every hour thereafter (NYDH, 2008:4).  
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Yet again, the U.S. Army Medical Research Institute of Chemical Defense 
(USAMRICD) provides slightly different instructions (USAMRICD, 2008:123-125). For 
mild symptoms, 2 mg of atropine and 600 mg of 2-Pam Cl are administered 
(USAMRICD, 2008:123-124). For severe symptoms, 6 mg of atropine and 1800 mg of 2-
Pam Cl are administered (USAMRICD, 2008:124). Additional doses of 2 mg of atropine 
are repeated every three to five minutes until breathing is near normal (USAMRICD, 
2008:123-124). There are no instructions for administering additional doses of 2-Pam Cl 
(USAMRICD, 2008:124). 
Finding the correct dosage of atropine is difficult (USAMRICD, 2008:124). There 
is a risk of giving too much atropine to a patient experiencing mild symptoms, and 
therefore, produce adverse effects on the patient from the atropine (USAMRICD, 
2008:124). In addition, there is a risk of giving too little atropine to a patient with severe 
symptoms, and experience the risk of not properly treating the patient (USAMRICD, 
2008:124).  
Table 1. Therapeutic Strategies for Mild to Moderate Symptoms 
  CDC NYPH USAMRICD 
Atropine Initial Dose 2 – 4 mg 2 – 4 mg 2 mg 
 Repeat Dose 2 mg Unspecified 2 mg 
 Repeat Interval 5 – 10 min 2 – 5 min 3 – 5 min 
2-Pam Cl Initial Dose 600 mg 600 mg 600 mg 
 Repeat Dose No Instructions 600 – 1200 mg No 
Instructions 
 Repeat Interval No Instructions Once b/w 30 – 60 
min 
& every hr 
thereafter 
No 
Instructions 
(CDC, 2008:13; NYDH, 2008:4; USAMRICD 2008:124) 
 
23 
 
Table 2. Therapeutic Strategies for Severe Symptoms 
  CDC NYPH USAMRICD 
Atropine Initial Dose 6 mg 6 mg 6 mg 
 Repeat Dose 2 mg Unspecified 2 mg 
 Repeat Interval 5 –10 min 2 – 5 min 3 – 5 min 
2-Pam Cl Initial Dose 1800 mg 1800 mg 1800 mg 
 Repeat Dose No Instructions 600 – 1200 mg No 
Instructions 
 Repeat Interval No Instructions Once b/w 30 –60 
min & every hr 
thereafter 
No 
Instructions 
(CDC, 2008:13, NYDH, 2008:4, USAMRICD 2008:124) 
 
Physiologically Based Pharmacokinetic Modeling 
 PPBK modeling describes the tissue-dose concentrations of a chemical with 
respect to time (Andersen, 2003:10).  A mass balance concept is applied to the model to 
describe absorption, distribution, metabolism and excretion of chemicals (Hoang, 
2003:99). Absorption, or entry, of a chemical into the model is primarily described by 
inhalation, dermal absorption, or ingestion (Hoang, 1995:101). Chemical excretion from 
the model occurs by metabolizing the chemical into an irrelevant metabolite, loss of the 
chemical in whole with urine, or volatilization of the chemical from the blood into the 
lungs (Hoang, 1995:102).  
Within the model, the entire mass of the organism under study is grouped into 
discrete tissue compartments with similar physiological and pharmacokinetic properties 
(Hoang, 1995:101).  Mass balance equations are created for each compartment to 
describe the concentration of the chemical in those compartments with respect to time 
(Hoang, 1995:101). 
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Figure 6. Basic PBPK Schematic (Gearhart and others, 1994:4) 
 Distribution of the chemical throughout the model occurs via the blood flow. The 
product of the fraction of blood flowing into each compartment, the concentration of the 
chemical in the blood (mass/volume), and the cardiac output (volume/time) determines 
the amount of chemical entering the compartment (mass/time). 
 Absorption of the chemical from the blood into the tissue compartment assumes a 
lumped-parameter approach (Hoang, 1995:101). In this assumption, the chemical 
completely diffuses from the blood into the tissue compartment and instantaneously 
achieves a homogenous and well-mixed state throughout the interstitial fluid of that 
compartment (Hoang, 1995:101). 
 A partition coefficient is used to describe the diffusion of the chemical from the 
tissue compartment into the venous blood flow. The amount of chemical leaving a 
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compartment (mass/time) is equal to the product of the fraction of blood flow from the 
compartment, the cardiac output (volume/time), the concentration of the chemical in the 
tissue compartment (mass/volume), and the inverse of the partition coefficient. A higher 
partition coefficient causes a slower outflow of the chemical from the compartment as 
compared to a lower partition coefficient. 
  Within each compartment, binding and bio-transformation of the chemical will 
affect the net accumulation rate of the chemical (Hoang, 1995:101). For example, 
mathematical equations are created to describe the alteration of chemicals to irrelevant 
byproducts through reaction with other chemicals and enzymes (Hoang, 1995:101).  
 PBPK modeling relies on pharmacokinetic data from laboratory experiments 
(Hoang, 1995:100). Typically, laboratory data are not complete (Hoang, 1995:100). 
Unknown parameters and metabolic constants are often determined or estimated through 
model fitting (Hoang, 1995:100). 
Chemical Reactions 
 One of the common chemical reactions that occur in the compartments of PBPK 
models is the metabolism of a chemical by an enzyme to an irrelevant metabolite (Hoang, 
1995:102). This chemical reaction is typically described as follows. 
          k1               k3 
 Enzyme + Substrate <-> Enzyme-Substrate Complex -> Enzyme + Product 
             k2  
 
 The chemical reaction can be mathematically expressed according to equation (1) 
(Clark, 1996:446). 
 d[Enzyme-Substrate Complex]/dt = k1[Enzyme][Substrate] 
         – k2[Enzyme-Substrate Complex] 
         – k3[Enzyme-Substrate Complex] (1) 
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Equation (1) is usually simplified to equation (2) (Clark, 1996:446-448).  
 d[Enzyme-Substrate Complex]/dt = (Vmax[Substrate])/(Km + [Substrate] (2) 
 Equation (2) is particularly useful since the coefficients, Vmax and Km, for this 
formula are found for many chemicals in literature. It is important to note that the enzyme 
is not destroyed in this reaction. This chemical reaction is applicable to the cytochrome 
P450 metabolism of organophosphates, atropine, and oximes. For reactions between 
organophosphates and esterases, the chemical reaction and equation (2) are not 
applicable. Esterases are destroyed with bond maturation. Hence the chemical reaction 
between organophosphates and esterase is more accurately expressed as follows.  
           k1     k3 
 Enzyme + Substrate <-> Enzyme-Substrate Complex -> Aged Enzyme-Substrate 
              k2  
 
 The chemical reaction is mathematically expressed according to equation (1) and 
cannot be simplified. 
Literature Data 
 Gearhart and others first applied PBPK modeling to organophosphates (Gearhart 
and others, 1994:1). Much of the basic model structure and data were incorporated into 
many of the organophosphate PBPK models found in literature that followed. In their 
study, Gearhart and others provided human physiological data such as body weight, 
ventilation rate, cardiac output, organ volumes, and fraction of blood flows to tissue 
groups (Gearhart and others, 1994:5). In addition, the researchers provided the partition 
coefficients and metabolic constants for the organophosphate, DFP (Gearhart and others, 
1994:3-6). These values are listed in Appendix B. 
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 Gentry and others investigated the effects of polymorphisms on the metabolism of 
parathion (Gentry and others, 2002:120). To conduct their study, the researchers needed 
to incorporate the kinetics between organophosphates and esterases into their model 
(Gentry and others, 2002:127-128). Initial concentration, synthesis constants, and 
degradation constants for the esterases were obtained from literature data, experiment, 
and model fitting. The constants were useful for this study and are listed in Appendix B.  
 In 2004, Ashani and Pistinner constructed a PBPK model to determine the use of 
exogenous butyrylcholinesterases as a prophylactic to protect against organophosphate 
poisoning (Ashani and Pistinner, 2004:358). Their model was based on the concept that 
free butyrylcholinesterases in the blood stream had the first opportunity to react with 
organophosphates (Ashani and Pistinner, 2004:359).  If enough butyrylcholinesterases 
were present in the blood stream, then much of the organophosphate would react with 
butyrylcholinesterases before the organophosphate could enter tissue groups and destroy 
acetylcholine esterases in those tissue groups (Ashani and Pistinner, 2004:359). 
Furthermore, because butyrylcholinesterases have a higher affinity for organophosphates 
as compared to acetylcholine esterases, exogenous butyrylcholinesterases would 
additionally protect some levels of acetylcholine esterases in the blood (Ashani and 
Pistinner, 2004:365). In their study, the researchers showed that between 48% and 68% 
of organophosphates were degraded in plasma before they ever reacted with esterases in 
tissue (Ashani and Pistinner, 2004:364). In addition, Ashani and Pistinner postulated with 
other researchers that acetylcholine esterase inhibition in tissue “should be well above 
65% to produce visible signs” of symptoms and that enzyme inhibition down to 10% of 
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basal levels may still permit critical physiological functions (Ashani and Pistinner, 
2004:365).  
 In 1985, Hinderling and others conducted a study to determine the 
pharmacokinetics of atropine (Hinderling and others, 1985:703). In two separate tests, the 
researchers intravenously dosed three human males with 1.35 and 2.15 mg of atropine 
(Hinderling and others, 1985:704). Plasma and urine levels of atropine and the atropine’s 
metabolite, tropine, were measured with a gas chromatographic mass spectrometry 
(Hinderling and others, 1985:703). The researchers determined that 57% of atropine was 
not metabolized and eliminated in whole in the urine (Hinderling and others, 1985:703).  
 A report for the International Program on Chemical Safety Evaluation in 2002 
provides a summary of atropine studies (Heath and McKeown, 2007:1).  The authors, 
Heath and McKeown, acknowledged that there is little understanding of the “optimal 
dose and pharmacokinetics of atropine in relation to the doses of oximes, the severity of 
(organophosphate) poisoning, and the properties of a particular organophosphate” (Heath 
and McKeown, 2007:30). In their report, the authors cited a study by Schoene and others 
that showed pre-dosing rats with atropine before the onset of organophosphate exposure 
reduced morality rates for the rats (Heath and McKeown, 2007:15). The authors cited 
another study by Matsubara and Horikoshi that suggested atropine alone was more 
effective than 2-Pam Cl in treating organophosphate poisoning (Heath and McKeown, 
2007:17). The authors further cited an additional experiment by Gupta, who dosed 
buffalo calves with an organophosphate, atropine, and 2-Pam Cl (Heath and McKeown, 
2007:17). Gupta suggested that a therapeutic strategy of atropine and 2-Pam Cl in 
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conjunction was more effective than either antidote working alone (Heath and McKeown, 
2007:17).  
 Heath and McKeown also reported on a study that stated atropine reaches a peak 
level in plasma at about 30 minutes after the administration of atropine (Heath and 
McKeown, 2007:22). Another study reported that only 5% of atropine remains in the 
blood after 5 minutes following an intravenous injection (Heath and McKeown, 
2007:23). A third study showed that atropine’s “initial distribution half-life is 
approximately one minute.” (Heath and McKeown, 2007:23). 
 Heath and McKeown point out the complications and difficulties in determining 
the optimal dose of atropine for organophosphate poisoning (Heath and McKeown, 
2007:24). Numerous case studies show the need for atropine doses ranging from 2 mg to 
as high as 50 mg, and some doses as much as 30,000 mg, over a period of 3 weeks (Heath 
and McKeown, 2007:24-25). Ultimately, the amount of atropine is determined by the 
observation of organophosphate induced symptoms (Heath and McKeown, 2007:26). 
 Little data is available for oximes and the antidote’s efficacy is in question. 
Szinicz and others reviewed and reported some of the complications of this antidote in a 
2007 paper (Szinicz and others, 2007:23). The researchers cited studies that confirm the 
efficacy of oximes for “in vitro and animal experiments” (Szinicz and others, 2007:25) 
However, “human reports of severe toxicity frequently mention the failure of oxime 
therapy and conclude oximes to be ineffective, or even harmful.” One of the suggestions 
for the failure of the oximes is that there is “re-inhibition of the reactivated enzyme by 
persisting organophosphates” in the body (Szinicz and others, 2007:26). The researchers 
suggest that future studies consider the total net effect of organophosphates and oximes 
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and consider “the various interactions between inhibitor, reactivator, and acetylcholine 
esterases” (Szinicz and others, 2007:26). 
 In a 1999 article, Thiermann and others presented and discussed the numerous 
chemical interactions among organophosphates, oximes, and enzymes (Thiermann and 
others, 1999:234). The researchers suggested that these chemical reactions can be 
expressed mathematically with reaction rate constants (Thiermann and others, 1999:234). 
 In 2007, Bartling, Worek, Szinicz, and Thiermann investigated the reactions 
between organophosphates and esterases (Bartling and others 2007:166). In their article 
the researchers provided chemical kinetic rate constants for several organophosphates, 
which proved useful for the work presented in this thesis (Bartling and others, 2007:169).  
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III. Methodology 
Modeling Tool 
Model construction and numerical integration was performed with the computer 
software, STELLA, version 8.0, developed by High Performance Systems Inc. 
Model Structure 
The model structure describing absorption, distribution, metabolism, and 
excretion was heavily based on physiological mechanisms and the model developed by 
Gearhart and others (Gearhart et. al. 1994:4). The basic model structure is depicted in 
Figure 7. The model neglected volume and mass of pulmonary tissue; however, a 
pulmonary compartment was created to describe pulmonary functions. 
Figure 7. Model Structure 
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The model described organophosphate absorption by inhalation and described 
atropine and oxime absorption by bolus intramuscular injections in the thigh tissue.  The 
model described chemical distribution by blood flow and described chemical excretion 
by loss with urine in the kidney compartment. Natural synthesis and degradation of 
esterases and acetylcholine molecules occurred solely within the compartments. 
Chemical reactions among organophosphates, esterases, acetylcholine molecules, 
atropine, and oximes occurred within each compartment. However, esterase 
concentrations were assumed to be negligible or non-existent in fat tissue, and therefore, 
no chemical reactions occurred in the fat compartment.  
Metabolism of organophosphates occurred by unspecified enzymes in all 
compartments except the fat compartment. In addition, degradation of organophosphates 
and esterases occurred by maturation of organophosphate-esterase bonds.  
Equations 
 A complete list of equations is provided in Appendix A. All equations for 
absorption, distribution, metabolism, and excretion were primarily based on concepts 
used by Gearhart and others. All equations for chemical reactions were based on concepts 
presented by Clark. 
 Equation (3) describes the general inflow and outflow of organophosphates, 
atropine, and oximes for each compartment.  
Accumulation = Inflow + Intramuscular Injection – Outflow 
         – Metabolism – Urinary Excretion    (3) 
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Natural synthesis and degradation of esterases occurred solely within the 
compartments and were described according to equation (4). Esterase levels were 
increased by a zero-order synthesis and decreased by first-order degradation. 
Esterase Level = Synthesis Constant 
          – Degradation Constant * Enzyme Concentration   (4) 
 
Chemical reactions between organophosphates and esterases were modeled 
according to the following chemical reaction.  
     l1             l3 
 Esterase + OP <-> Esterase-OP Complex -> Aged Esterase-OP  
     l2  
 
The chemical reaction was mathematically expressed according to equation (5). 
d[Esterase-OP]/dt = k1[Esterase][OP] - k2[Esterase-OP] 
                                             – k3[Esterase-OP]     (5) 
 
 Chemical reactions between organophosphate-esterase complexes and oximes 
were based on the following chemical reaction. 
    o1 
 Esterase-OP + Oxime -> Esterase + OP + Oxime 
 
 The chemical reaction was mathematically expressed according to equation (6). 
 -d[Esterase-OP]/dt = o1[Esterase-OP][Oxime]    (6) 
 The model described a homeostatic condition of acetylcholine molecules at the 
binding sites with acetylcholine esterases. This condition represented one mole of 
acetylcholine molecules for every mole of acetylcholine esterases in each tissue 
compartment, except the fat compartment. The homeostatic condition was represented by 
a zero-order binding rate of acetylcholine molecules to acetylcholine esterases and a 
second-order hydrolysis of acetylcholine molecules by acetylcholine esterases. 
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 d[ACh-AChE]/dt = p1 – p2[AChE][ACh-AChE]    (7) 
 Atropine does not directly interact with organophosphates or biological 
chemicals. Instead it reacts only with the neural receptor sites and limits acetylcholine’s 
access to these sites. A simple ratio was incorporated into equation (7) that dampens the 
inflow of acetylcholine molecules to the binding sites and thereby integrates the effects of 
atropine. 
 d[ACh-AChE]/dt = p1{p1/( p1 + [Atropine])} - p2[AChE][ACh-AChE] (8) 
 Equation (8) simplifies to equation (7) when no atropine is present. In this 
situation, the amount of acetylcholine molecules flowing into the binding sites is normal. 
If atropine is introduced, the net rate of acetylcholine molecules binding to acetylcholine 
esterases is reduced. If acetylcholine esterase levels drop as a result of chemical reactions 
with organophosphates, the outflow of acetylcholine molecules from equation (8) is 
dampened and results in a net increase of acetylcholine molecules at the binding sites.  
 Symptoms were described as a ratio between the amount of acetylcholine 
molecules at the acetylcholine binding sites and the basal level of acetylcholine 
molecules at the binding sites. This quantitative representation of symptoms was used as 
the primary index to compare therapeutic strategies. 
 dSymptoms/dt = [ACh-AChE site]/[Basal ACh-AChE site]   (9)  
Assumptions 
The model structure and the physiological mechanisms it is based on are drawn 
from current understanding of physiology, biological chemicals, organophosphates, and 
antidotes. Many of these mechanisms are vaguely or incompletely understood. In 
addition, the model attempts to simplify mechanisms where possible. Furthermore, much 
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pharmacokinetic data is incomplete for these chemicals. Although there are several minor 
assumptions, critical model assumptions are provided as follows.  
1. Lumped-parameter distribution assumes instantaneous equilibration between 
tissue and blood and well-mixed distribution of the chemical within the interstitial 
fluid. 
2. Metabolism of chemicals by the cytochrome P-450 enzyme suite follows 
Michaelis-Menten kinetics. 
3. The release of acetylcholine from the pre-synaptic nerve cell and diffusion of the 
neurotransmitters across the synaptic cleft occurs so rapidly that it is assumed to 
be constant and continuous. 
Parameters and Coefficients 
 Parameters and coefficients were either obtained from literature or fitted to the 
model to produce results that mimicked observations presented in literature. All 
parameters and coefficients used in the model are listed in Appendix B.  
Diisopropylfluorophosphate (DFP) data were obtained from Gearhart and others. This 
data were applied to the model to describe a typical organophosphate.  
Very little pharmacokinetic data are available for atropine and oximes. 
Application of partition coefficients and metabolic constants from DFP data to describe 
the antidotes produced model results that generally mimicked limited observations of the 
antidotes described in research literature. In addition, a kidney elimination constant of 
0.35 for the antidotes produced reasonable elimination of the antidotes, in whole, from 
the model with urine excretion. 
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 Synthesis rates and initial amounts of esterases were obtained from Gentry and 
others. Degradation constants were calculated to maintain steady-state levels in each 
tissue compartment.  
Acetylcholine molecules were assumed to continuously occupy all binding sites 
of acetylcholine esterases at a one-to-one molar ratio. Chemical reaction rate coefficients 
were calculated to maintain this ratio under normal conditions.  
Bartling and others provided some reaction rate coefficients between esterases 
and organophosphates. It is known that butyrylcholinesterases have a higher affinity for 
organophosphates than acetylcholine esterases, and acetylcholine esterases have a higher 
affinity for organophosphates than carboxylesterases (Ashani and Pistinner 2004:365). 
The organophosphate reaction rate with butyrylcholinesterases and carboxylesterases was 
linked to the reaction rate with acetylcholine esterases. Butyrylcholinesterases were set to 
be twice as reactive with organophosphates as compared to acetylcholine esterases. 
Carboxylesterases were set to be half as reactive with organophosphates as compared to 
acetylcholine esterases.   
Ashani and Pistinner suggested that acetylcholine esterase levels at 65% of basal 
levels were required to observe noticeable organophosphate induced symptoms, and 
acetylcholine esterase levels at 10% of basal levels were critical to life sustaining 
functions (Ashani and Pistinner 2004:365). In the model, an inhibition of acetylcholine 
esterases to 65% of basal levels produced a symptom level of 1.09, and an inhibition of 
acetylcholine esterases to 10% of basal levels produced a symptom level of 1.16. With no 
inhibition of acetylcholine esterases, the standard symptom level was 1.0.  
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Literature suggested that atropine doses of 10mg without organophosphate 
poisoning also produced adverse symptoms (USAMRICD 2000:120). Application of 10 
mg of atropine to the model produced a peak atropine level of 0.08 mg in the brain 
compartment at 9 minutes and corresponded to a symptom level of 0.89. The symptom 
level continued to decline to a low value of 0.45 at 97.8 minutes. It was assumed that 
symptom levels below 0.91 produced adverse effects from atropine and symptom levels 
below 0.84 for 10 minutes or longer produced death from atropine. 
Sensitivity Testing 
 For sensitivity testing, 10 mg of organophosphate per liter of air was applied to 
the model, beginning at time 0, for 15 minutes. In addition, 2 mg of atropine and 600 mg 
of oxime were added at time 0. The maximum value of the symptom level was measured 
and recorded. Each of the model parameters and coefficients was changed to a 50% and 
150% value. The model was individually run for each change in parameters and 
coefficients, and the maximum value of the symptom level was recorded.  
 The greatest variability of symptoms rested with the reaction rate coefficient 
between acetylcholine esterases and the organophosphate. This result would show strong 
support that variability of organophosphate toxicity among different types of 
organophosphates rests greatest with the reaction rates between the organophosphates and 
acetylcholine esterases. Of less variability, but noticeable, were the partition coefficients 
of the organophosphate. As the partition coefficients of the organophosphate increased, 
organophosphate persisted longer in the tissue compartments and reacted with more 
acetylcholine esterases. In addition, the partition coefficients of atropine also had a 
noticeable impact on symptom levels. As the partition coefficients of atropine increased, 
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atropine persisted in the tissue compartments and countered the effects of excessive 
neural stimulation for a longer period of time.  
 Although the partition coefficients of the organophosphate had an impact on the 
symptom level, the DFP data provided by Gearhart and others was used as the standard 
organophosphate, representing all varieties of organophosphorus chemicals. 
Consequently, the major factors that would affect the differences in toxicity of 
organophosphates in the model would result from the different reaction rate coefficients 
with acetylcholine esterases. 
 Although the partition coefficients of atropine affected symptom levels, the 
applied parameter values reasonably mirrored anecdotal observations of atropine. 
Furthermore, there is no variability among a class of atropine as there is with 
organophosphates. Therefore, maintaining atropine parameters at the values initially 
suggested is reasonable and permits fair comparison among the tests.  
Test Protocol 
Initially, two types of theoretical organophosphates were created for the study. 
The first organophosphate reacted rapidly with acetylcholine esterases, and the 
organophosphate-acetylcholine esterase bonds matured quickly and responded poorly to 
oximes. In comparison, the second organophosphate reacted slowly with acetylcholine 
esterases, and organophosphate-acetylcholine esterase bonds matured slowly and 
responded favorably to oximes.  
A series of 19 tests were run for each organophosphate type. The tests are 
described in Table 3 of Appendix C. Series A tests incorporated the more toxic 
organophosphate and Series B tests incorporated the less toxic organophosphate. For each 
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test, the time symptoms first appeared, the length of time symptoms persisted, and the 
total amounts of antidotes administered were recorded. Each test applied an 
organophosphate exposure of 5 mg per liter of air for 15 minutes beginning at +5 
minutes.  
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IV. Results and Analysis 
Appendix C provides all test protocols and detailed results. 
Series A and B Tests 
 The organophosphate exposure depressed acetylcholine levels and increased 
symptom levels for both series of tests. Noticeable symptoms appeared at approximately 
20 minutes for Series A tests and at 35 minutes for Series B tests after organophosphate 
exposure began. 
Increasing and decreasing rates of symptom levels at the end of 3 hours were 
dependent on the amount of atropine in the tissue at that time. Therefore, it is expected 
that all symptom levels will eventually return to higher levels beyond 3 hours until 
acetylcholine esterase levels return to normal. 
Atropine appeared to have immediate impacts on suppressing symptom levels. In 
tests, where only atropine was used, symptom levels remained above noticeable levels for 
only 1.2 to 8.4 minutes after the first injection of atropine.  
In general, strictly time-based dosing strategies for atropine appear excessive and 
wasteful. In both series, where only atropine was used, continuous interval dosing of 
atropine led to a build-up of the antidote in the tissue and a prolonged level of critical 
symptoms resulting from atropine toxicity. Conversely, it would seem that longer dosing 
intervals between atropine administrations would risk the scenario of not administering 
enough atropine to suppress organophosphate induced symptoms. In addition, after 
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comparing the tests between the two series, the duration of symptom levels with the 
presence of atropine varied with the organophosphate toxicity.  
In just three hours, 56 to 72 mg of atropine were needed in a time-based dosing 
strategy, which corresponds to 28 to 36 injections of atropine. A symptoms-based dosing 
strategy for the same organophosphate exposures, required only 2 to 4 mg of atropine, 
corresponding to 1 to 2 injections of atropine, to keep symptoms suppressed. The 
symptoms-based dosing strategy required 1% to 3% of the total atropine used in the time-
based dosing strategy and did not produce atropine toxicity. 
Administering atropine before the onset of organophosphate exposure appears to 
delay the onset of symptoms. In Series A, a pre-dose administration of atropine delayed 
onset of symptoms by 69.2 minutes as compared to administering atropine upon the 
appearance of noticeable symptoms. Similar results were found when comparing tests of 
Series B. 
Oxime treatment yielded poor results. In tests where only oximes were 
administered, the oximes failed to suppress symptom levels. It is possible that the 
organophosphates used in the tests were too toxic for the oximes to overcome. 
There is a delay between the time organophosphate exposure begins and the first 
observation of symptoms. Symptoms appeared nearly 20 minutes after the onset of 
organophosphate exposure. This delay between exposure and symptoms results from the 
fact that acetylcholine esterase levels must be degraded to 65% of basal levels before 
symptoms first appear. The model was constructed to ensure oximes break 
organophosphate-acetylcholine esterase bonds. However, oximes are at a severe time 
disadvantage in performing their function when they are introduced at the onset of 
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symptoms. A full 20 minutes would elapse between organophosphate exposure and 
symptoms induced oxime injection. As a result, some organophosphate-acetylcholine 
esterase bonds can mature before oximes ever have a chance to perform their function. 
Atropine is at a similar disadvantage, but to a less severe degree. First atropine’s 
therapeutic effect is not directly dependent on acetylcholine esterase levels. Second, as 
noted earlier, atropine reacts quickly to suppress symptoms. 
Another possibility for the failure of oximes may rest with the understood 
mechanisms of organophosphate toxicity, and therefore, the structure of the model. The 
model was created to allow organophosphates the ability to rebind with acetylcholine 
esterases after the organophosphates were freed by oximes from initial bonds with 
acetylcholine esterases. In this model structure, a mass of organophosphate and a mass of 
acetylcholine esterase will bind together during a single time increment. For the next time 
increment, some of the organophosphate-acetylcholine esterase mass ages and some of 
the organophosphate-acetylcholine esterase mass is broken apart by the oxime. For the 
third time increment, some of the freed acetylcholine esterases and organophosphates 
immediately re-bind. This cycle repeats, and the oxime is in a losing battle since a portion 
of the organophosphate-acetylcholine esterase mass ages with each time increment.  
Series C Tests 
To explore the possibility that a continuous cycle of binding and rebinding 
between organophosphates and acetylcholine esterases mitigates or negates the effects of 
oximes, the model was restructured so that freed organophosphates by oximes were 
unable to rebind with acetylcholine esterases. Under this new model structure, the tests in 
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Series B were repeated. The results for Series C tests were identical to the results of 
Series B tests. Again, oximes were unable to suppress symptom levels.  
Series D and E Tests 
The inability of oximes to reduce symptom levels or the onset of symptoms was 
disturbing. As a result, additional tests were undertaken to determine if the 
organophosphate toxicity was too severe in comparison to the oxime therapeutic ability.  
 The new test protocols varied the reaction rate coefficients among the chemicals 
and applied an organophosphate exposure and a time-based dosing strategy for oxime 
treatment. Series D tests used the model structure in which freed organophosphates were 
unable to reactivate with acetylcholine esterases once the organophosphates were freed 
from bonds with the esterases by oximes. Series E tests used the model structure in which 
freed organophosphates were able to reactivate with acetylcholine esterases once the 
organophosphates were freed from bonds with the esterases by oximes.  
 Oximes show some efficacy in both test series when the aging rate of the 
organophosphate-acetylcholine esterase bonds was significantly lowered. For Series D, 
oximes reduced the destruction of acetylcholine esterases by nearly 11.5% as compared 
to the same organophosphate exposure with no oxime dose. For series E, oximes reduced 
the destruction of acetylcholine esterases by approximately 9.8% as compared to the 
same organophosphate exposure with no oxime dose. These results suggest two findings. 
First, oximes are slightly more effective if the organophosphates are unable to rebind 
with acetylcholine esterases after the organophosphates are freed from bonds with the 
esterases by oximes. Second, oxime efficacy is sensitive to the organophosphate-
acetylcholine esterase maturation rate coefficient. 
 
44 
 
 
Series F Tests 
For Series F tests, more attention was given to the maturation rate coefficients. 
The maturation half-lives of some nerve agents are well known. Soman-acetylcholine 
esterase bonds have an maturation half-life of less than 10 minutes, sarin-acetylcholine 
esterase bonds have an maturation half-life of 5 hrs, and VX-acetylcholine esterase bonds 
have an maturation half-life of approximately 48 hours (Cannard 2006:89).  
Using equation (10), λ was calculated for half-lives of 10 minutes, 5 hours, and 
48 hours. With equation (11), the maturation rate coefficients were then found through 
model fitting.  
Half-Life = .693/λ        (10)  
            A = Aoe-λt         (11) 
 Furthermore, the reaction rate coefficients between organophosphates and 
acetylcholine esterases were refined based on literature data. Thiermann and others 
present reaction rate coefficients of 132,000 mmol-1hr-1 and 1320 mmol-1hr-1 for two 
organophosphorus insecticides (Thiermann and others, 1999:234). Bartling and others 
provide reaction rate coefficients for some nerve agents ranging between 660,000    
mmol-1hr-1 and 31,800,000 mmol-1hr-1 (Bartling and others, 2007:169). Using the 
calculated maturation rate coefficients and using the reaction rate coefficients between 
organophosphates and acetylcholine esterases of 1,000,000 mmol-1hr-1 and 50,000   
mmol-1hr-1, organophosphates and oximes were applied to the model.  
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There were four significant findings from this series of tests. First, when the 
amount of organophosphates and time of organophosphate exposure is increased, the 
efficacy of oximes is reduced. Second, when oximes are administered before 
organophosphate exposure begins, more acetylcholine esterases are recovered over time. 
Third, oximes appear to have no positive effect on suppressing symptoms when the 
reaction rate between organophosphates and acetylcholine esterases is relatively high and 
the maturation half-life of organophosphate-acetylcholine esterase bonds is also high. 
Finally, in certain conditions, oximes appear to make acetylcholine esterase levels lower 
and symptom levels higher than if no oximes were administered at all. 
The last finding is illustrated in Figure 8. Figure 8 depicts the test in which 5 mg / 
L of organophosphate was applied for 15 minutes from time +5 to time +20 minutes. In 
this test, the reaction rate coefficient between organophosphates and acetylcholine 
esterases was relatively high and the maturation half-life of organophosphate-
acetylcholine esterase bonds was 5 hours. An oxime injection of 600 mg was 
administered upon the first appearance of noticeable symptoms and 600 mg of oxime 
were administered every 5 minutes thereafter. In this graph, acetylcholine esterase levels 
immediately dropped with the presence of organophosphate exposure. With the 
administration of oximes, acetylcholine esterase levels dropped further and then began to 
improve. 
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Figure 8. Organophosphate Exposure with Continuous Oxime Treatment 
When only one injection of 600 mg of oximes was administered at the appearance 
of noticeable symptoms, acetylcholine esterase levels dropped and failed to improve. 
This scenario is illustrated in Figure 9 and suggests that oximes made organophosphate 
poisoning worse.  
Figure 9. Organophosphate Exposure with One Oxime Injection 
One of the reasons why the oximes may make acetylcholine esterase levels worse 
is the fact that the reaction rate coefficients between oximes and esterases vary. The 
organophosphate’s affinity for esterases decreases, in order, with butyrylcholinesterases, 
acetylcholine esterases, and carboxylesterases. There is a potential that the oxime is 
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breaking organophosphate-esterase bonds, and that a higher proportion of 
organophosphates, originally bound to carboxylesterases, are now binding with 
butyrylcholinesterases and acetylcholine esterases. If this mechanism is true, 
carboxylesterase levels should increase with time after the injection of oximes. Figure 10 
shows the esterase levels for the same organophosphate exposure and one injection of 
600 mg of oxime. All three esterase levels decrease to lower levels after the injection of 
oxime. Therefore, although organophosphates released from bonds with 
carboxylesterases may be disproportionately rebinding with acetylcholine esterases and 
butyrylcholinesterases, it is not the determining cause of lower acetylcholine esterase 
levels. 
Figure 10. Esterase Levels in Brain Compartment 
Figure 11 shows carboxylesterase levels in other tissue compartments of the 
model. As with Figure 10, carboxylesterase levels are decreasing after the injection of 
oximes. 
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Figure 11. Carboxylesterase Levels in Various Tissue Compartments 
Figure 12 shows esterase levels in the arterial compartment. The figure shows that 
all esterase levels improve after the oxime injection. Therefore, it appears that oximes are 
effectively breaking organophosphate-enzyme bonds in the arterial compartment and 
restoring some levels of these esterases. However, the released organophosphate is 
diffusing into the other tissue compartments and lowering esterase levels in those 
compartments.  
Figure 12. Esterase Levels in Arterial Compartment 
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The phenomenon that oximes may make organophosphates poisoning worse 
results from physiology and the model structure. Organophosphates enter the model 
through the lung compartment, proceed through the arterial compartment, and then pass 
through tissue compartments. Esterases in the arterial compartment are the first to react 
with and most severely affected by organophosphates. 
This reasoning was explored by Ashani and Pistinner in 2003. In their study, the 
researchers used exogenous butyrylcholinesterases as a prophylactic against 
organophosphate poisoning. The researchers believed that since butyrylcholinesterases 
have a higher affinity to organophosphates, excess butyrylcholinesterase levels in the 
blood would react in greater numbers with organophosphates. As a result, fewer 
organophosphates would react with acetylcholine esterases in the blood and fewer 
organophosphates were able to diffuse into the tissue compartments. (Ashani and 
Pistinner, 2003:358-367) 
This same reasoning may explain why oximes are causing acetylcholine esterase 
levels to drop to lower levels in the tissue compartment. Organophosphate-esterase bonds 
in the blood are the first benefited by oximes. The oximes are improving esterase levels 
in the blood, but freed organophosphates are diffusing into tissue compartments and 
reacting with esterases in these tissue compartments. 
Research literature supports this finding. In a 2007 article, Szinicz and others 
reviewed the efficacy of oxime treatment. The authors stated “human reports of severe 
toxicity frequently mention failure of oxime therapy and conclude oximes to be 
ineffective, or even harmful” (Szinicz and others, 2007:25).  Furthermore, citing other 
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studies, the authors note that “disappointing results were found when … oxime 
administration was discontinued prematurely” (Szinicz and others, 2007:27). 
Szinicz and other suggested that the failure of oximes may result from freed 
esterases rebinding with persisting organophosphates in the body (Szinicz and others, 
2007:26). This suggested mechanism may complement the causes of oxime failure. 
However, the model suggests that there are three determining and interdependent causes 
of oxime failure for highly toxic organophosphates. First, the antidote disproportionately 
breaks more organophosphate-esterase bonds in the blood as compared to 
organophosphate-esterase bonds the tissue groups. Second, the freed organophosphates in 
the blood are rebinding in greater numbers with esterases in the tissue groups. Finally, the 
oxime reaction rate to break organophosphate-esterase bonds and the time elimination of 
oximes from the body cannot overcome the affinity of organophosphates for esterases.  
Although laboratory procedures to measure organophosphates poisoning and 
acetylcholine esterase levels were not included in the scope of this study, the model 
suggested interesting findings that may be relevant for these procedures. Scientists and 
medical doctors typically measure acetylcholine esterase levels in the blood to determine 
the severity of organophosphate poisoning and the efficacy of oximes. The model 
suggests that this measurement technique may provide misleading results. The oxime 
may be improving esterase levels in the blood while simultaneously lowering esterase 
levels in tissue groups, where acetylcholine esterases are more critical to proper 
physiological functioning.    
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V. Discussion 
Research Objectives 
This research set out to accomplish four objectives.  
1. Construct a physiologically based pharmacokinetic model (PBPK) to predict the tissue 
concentrations of organophosphates, atropine, oximes, and pertinent biological 
chemicals. 
Although very little data are available to accurately predict tissue concentrations 
for atropine and oxime, model fitting the parameters reasonably represented literature 
observations. In addition, the partition coefficients and metabolic constants were 
available for only a few organophosphates. A sensitivity test revealed that the parameters 
for all of these chemicals had little impact on the outcome of human response. Research 
revealing more accurate constants would likely produce more refined results. Such 
refinement, however, given the results of the sensitivity analysis, would not be expected 
to alter the conclusions of this work. 
The PBPK model could incorporate two additional elements of organophosphate 
poisoning that may provide beneficial information. First, the entry routes of 
organophosphates could include ingestion and dermal absorption. Second, the toxic 
effects of some organophosphates, such as parathion, result from the metabolite of the 
chemical and not the chemical itself. Modeling these intake routes and metabolites would 
likely alter time distribution of the chemical and the severity and onset of symptoms.  
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2. Integrate the reactions among these chemicals into the model and produce a 
quantitative measurement of their aggregate effects. 
The equations to represent accumulation of acetylcholine molecules at the neural 
synapse and symptom levels appeared to produce results that followed observed 
outcomes of organophosphate poisoning. The equations were simple and allowed for easy 
comparison among different organophosphate exposures and therapeutic strategies.  
However, it is important to note that atropine and oximes mitigate different symptoms of 
organophosphate poisoning, because the antidotes work at different types of neural 
receptors. The tests conducted in this work included administering atropine and oximes 
separately; and therefore, future refinement of the equations would not be expected to 
alter the conclusions of this work.  
The reactions among the chemicals appear to have had the most dominant affect 
on the outcome of acetylcholine esterase and symptom levels. Applying the entire variety 
of kinetic reaction rate constants will likely help to refine the efficacy of oximes in 
relation to the various organophosphates. However, as with the chemical parameters, 
such refinement would not be expected to alter the major conclusions of this work. 
3. Apply therapeutic strategies for atropine and oximes against an organophosphate 
exposure to the model. 
This thesis reviewed time-based dosing of antidotes, symptoms-based dosing of 
antidotes, administering antidotes upon the appearance of symptoms, and administering 
antidotes before the onset of organophosphate exposure. Symptoms-based dosing of 
atropine proved most economical and ensured correct amounts of the antidote were 
administered to properly treat organophosphate poisoning and prevent adverse effects of 
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atropine toxicity. Although agencies may find it easier to mass educate a time-based 
dosing strategy for atropine, allocating resources to educate medical technicians and 
military personnel about the intricacies of organophosphate induced symptoms may 
better serve the patient and conserve the medication.  
In certain scenarios, when oximes were effective, a time-based dosing strategy of 
oximes proved most prudent. There is a delay between the time organophosphates bind to 
acetylcholine esterases and the appearance of symptoms. During this time delay, some 
organophosphate-acetylcholine esterase bonds begin to mature. It is imperative that 
oximes are introduced early and maintain presence in the tissue groups until 
organophosphates are completely removed from the body. A time-based application of 
oximes would maintain oxime levels between an ideal range in the tissue groups. 
Personnel at medical facilities could ensure the ideal range of oxime levels in the tissue 
groups persisted until the removal of all organophosphates from the body. 
Current procedures for medical facilities to administer antidotes are slightly 
different than procedures for first care responders. Medical facilities have the ability to 
administer the antidotes intravenously, normally have greater quantities of the antidotes, 
and will potentially have to manage a patient for weeks until the full recovery of 
acetylcholine esterases. It is possible the dynamics of organophosphate poisoning and the 
optimal strategies for antidote administration are slightly different for long-term 
treatment than what has been suggested in this study. Investigation into this long-term 
treatment may be worthy for future research.  
4. Compare model output and report significant differences among therapeutic strategies. 
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Test results revealed five important findings. First, application of antidotes before 
organophosphate exposure began tended to delay the onset and reduce the severity of 
symptom levels. Although this finding is beneficial, the ability of individuals to anticipate 
organophosphate exposure and preempt the poisoning with antidote treatment is highly 
improbable. 
Second, oxime efficacy decreases with the exposure duration and toxicity of 
organophosphates. Although this may be an obvious and expected finding, the finding 
does suggest that when the severity of organophosphate poisoning reaches a certain level, 
oximes may no longer be effective in recovering any significant amounts of acetylcholine 
esterases. This point was shown when an organophosphate with a kinetic reaction rate 
constant similar to nerve agents and an aging half-life of 10 minutes was applied to the 
model. Excessive oxime doses failed to recover any noticeable amounts of acetylcholine 
esterases. 
Third, oximes efficacy improves if organophosphates cannot reactivate with 
acetylcholine esterases once the organophosphates are freed by oximes from the 
esterases. The ability for organophosphates to rebind with acetylcholine esterases is 
suspected but is not definitively known for all organophosphate types.  
Fourth, there is a time delay between organophosphate exposure and the 
appearance of noticeable symptoms. The time delay varies with the toxicity of the 
organophosphate and the duration of organophosphate exposure. The time delay appears 
to have no significant bearing on atropine efficacy. The benefits of atropine appear 
largely independent of acetylcholine esterase levels and occur rather quickly. If oximes 
are introduced when symptoms first appear, there is a potential that irreversible 
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maturation of the organophosphate-acetylcholine esterase bond has already occurred. For 
the condition when the aging half-life of organophosphate-acetylcholine esterase bonds is 
relatively high, it is unlikely that copious doses of oximes will have any positive effect on 
recovery of acetylcholine esterase and reducing symptom levels. However, oximes could 
be significantly effective if oximes are introduced when symptoms first appear and if the 
organophosphate-acetylcholine esterase aging rate coefficient is relatively low. Under 
this condition, it is likely that oximes will help restore some, and possibly significant, 
portions of acetylcholine esterase to a functional state.  
Finally, under certain conditions, such as when the kinetic reaction rate 
coefficient between organophosphates and acetylcholine esterases is relatively high and 
the aging half-life of organophosphate-acetylcholine esterase bonds is moderate, oximes 
depress acetylcholine esterase levels in tissue groups. The model suggests that oximes 
effectively free organophosphate-enzyme bonds in the arterial compartment. However, 
freed organophosphates diffuse into the other tissue groups, quickly react with esterases, 
and cause esterase levels to decrease in those tissue groups. If continuous doses of 
oximes are applied, acetylcholine esterase levels will eventually improve. However, 
enough oxime must be continuously administered and the body must be able to tolerate 
the large quantities of required oximes to achieve a positive effect.  
Recommendations 
There are two likely situations that involve organophosphate poisoning. First, 
people living and working in rural, agricultural areas may become poisoned through 
improper application and accidental exposure to organophosphorus insecticides. These 
organophosphates tend to have low reaction rate coefficients with acetylcholine esterases 
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and moderate to low aging half-lives of organophosphate-acetylcholine esterase bonds. 
The model suggests that first care responders should administer atropine on a symptoms-
based dosing strategy to ensure proper suppression of symptoms and limit adverse affects 
of atropine toxicity. In addition, first care responders should administer oximes early and 
continuously until further tests and time assure the complete removal of 
organophosphates from the body. Oximes appear quite effective for relatively weak 
organophosphates. 
Organophosphate poisoning for people living in urban areas and military 
personnel involved in conflicts will likely result from either a terrorist event or a military 
weapon.  It is highly probably that these organophosphates are of the nerve agent variety, 
which have a high reaction rate coefficient with acetylcholine esterases. Again, the model 
suggests that symptoms-based dosing of atropine is the most economical use of the 
antidote. In addition to properly treating the patient, conservation of atropine could be 
crucial when atropine supplies are limited. A terrorist event could involve mass casualties 
and deployed military personnel only carry 6 mg of atropine on their persons. 
Furthermore, the model suggests first care responders to a terrorist event or military 
personnel in conflict should not administer oximes. It is likely that the oximes are not 
effective, and in some cases, cause the severity of organophosphate toxicity to increase.  
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Appendix A. Equations 
Organophosphates 
Slowly Perfused, Thigh Tissue, Diaphragm Tissue, and Fat Tissue 
dA/dt = F * CA - F * QC * CV / BW / NF / P 
Brain, Liver, Kidney, and Rapidly Perfused Tissue 
dA/dt = F * CA - F * QC * CV / BW / NF / P - (Vmax * CV / BW / 
   NF)/(KM + CV / BW / NF) 
Venous Compartment 
dA/dt = E (CV) - QC * CV1 / P - (Vmax * CV1 / BW / NF)/(KM + CV1 / 
BW / NF) 
Lung Compartment 
QP * Cexp + CV1 = QP * CA1 / P + QC * CA1 
Arterial Compartment 
dA/dt = QC x CA1 - QC x CA / P - (Vmax * CV / BW / NF)/(KM + CV / 
BW / NF)  
 
Oxime 
Brain, Diaphragm, Fat, Richly Perfused, Slowly Perfused, and Thigh Tissues 
dA/dt = F * CA - F * QC * CV / BW / NF / P 
Kidney Tissue 
dA/dt = F * CA - F * QC * CV / BW / NF / P - EP * CV 
Liver Tissue 
dA/dt = F * CA - F * QC * CV / BW / NF / P - (Vmax * CV / BW / 
NF)/(KM + CV / BW / NF) 
Venous Compartment 
dA/dt = E (CV) - QC * CV/ P 
Lung Compartment 
QP * Cexp + CV1 = QP * CA1 / P + QC * CA1 
Arterial Compartment 
dA/dt = QC x CA1 - QC x CA / P 
 
Atropine 
Brain, Diaphragm, Fat, Richly Perfused, Slowly Perfused, and Thigh Tissues 
dA/dt = F * CA - F * QC * CV / BW / NF / P 
Kidney Tissue 
dA/dt = F * CA - F * QC * CV / BW / NF / P - EP * CV 
Liver Tissue 
dA/dt = F * CA - F * QC * CV / BW / NF / P - (Vmax * CV / BW / 
NF)/(KM + CV / BW / NF) 
Venous Compartment 
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dA/dt = E(CV) - QC * CV/ P 
Lung Compartment 
QP * Cexp + CV1 = QP * CA1 / P + QC * CA1 
Arterial Compartment 
dA/dt = QC x CA1 - QC x CA / P 
 
Acetylcholinesterase 
Brain, Kidney, Diaphragm, Liver, Slowly Perfused, Richly Perfused, and Thigh 
Tissues 
dA/dt = X1 - X2A 
 
Butyrylcholinesterase 
Brain, Kidney, Diaphragm, Liver, Slowly Perfused, Richly Perfused, and Thigh 
Tissues 
dA/dt = Y1 - Y2A 
 
Carboxylesterase  
Brain, Kidney, Diaphragm, Liver, Slowly Perfused, Richly Perfused, and Thigh 
Tissues 
dA/dt = Z1 - Z2A 
 
Acetylcholinesterase and Organophosphate Chemical Reaction 
 L1      L3  
AChE  +  OP  <--->  AChE/OP  --->  Aged AChE/OP 
 L2 
d[AChE/OP]/dt = L1 * [AChE] * [OP] – L2 [AChE/OP] – L3 [AChE/OP] 
 
Butyrylcholinesterase and Organophosphate Chemical Reaction 
   M1          M3 
BuChE  +  OP  <--->  BuChE/OP  --->  Aged BuChE/OP 
   M2 
d[BuChE]/dt = M1 * [BuChE] * [OP] – M2 * [BuChE/OP] – M3 * 
[BuChE/OP] 
 
Carboxylesterase and Organophosphate Chemical Reaction 
          N1           N3 
CaE  +  OP  <--->  CaE/OP  --->  Aged CaE/OP 
          N2 
d[CaE/OP]/dt = N1 * [CaE] * [OP] – N2 [CaE/OP] – N3 [CaE/OP] 
 
Oxime and AchE/OP Chemical Reaction 
O1 
AChE/OP  +  Oxime  --->  AChE  +  OP  +  Oxime 
-d[AChE/OP]/dt = O1 * [AChE/OP] * [Oxime] 
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Oxime and BuChE/OP Chemical Reaction 
   P1 
BuChE/OP  +  Oxime  --->  BuChE  +  OP  +  Oxime 
-d[BuChE/OP]/dt = P1 * [BuChE/OP] * [Oxime] 
 
Oxime and CaE/OP Chemical Reaction 
        R1 
CaE/OP  +  Oxime  --->  CaE  +  OP  +  Oxime 
-d[CaE/OP]/dt = R1 * [CaE/OP] * [Oxime] 
 
Atropine, Acetylcholine, and Acetylcholine Esterase Reaction 
d[ACh-AChE]/dt = p1{p1/( p1 + [Atropine])} - p2[AChE][ACh-AChE] 
 
Symptoms 
dSymptoms/dt = [ACh-AChE site]/[Basal ACh-AChE site] 
 
Legend 
dA/dt = change in chemical accumulation with respect to time (mass / time) 
F = Fraction of blood flow that enters the tissue (unitless) 
CA = Arterial Blood Outflow (mass / time) 
QC = Cardiac Output (volume / time) 
CV = Mass of OP in tissue (mass) 
BW = Body Weight (mass) 
NF = Normalization Factor (volume of tissue / mass of body weight) 
P = Tissue to blood partition coefficient (unitless) 
KM = Michaelis-Menten Constant (mass / volume) 
Vmax = Maximum metabolism rate of OP (mass / time) 
CA1 = arterial concentration (mass / volume) 
QP = pulmonary ventilation rate (volume / time) 
Cexp = concentration of chemical in alveolar space (mass / volume) 
CV1 = venous blood output (mass / time) 
P = air to blood partition coefficient (unitless) 
QC = cardiac output (volume / time) 
K = conversion factor to convert kg of air to L of air = 0.001204 kg of air / L of air 
EP = Elimination parameter of pure oxime into urine. (time-1) 
X1 = AChE synthesis rate (mass / time) 
X2 = AChE degradation constant (time-1) 
Y1 = BuChE synthesis rate (mass / time) 
Y2 = BuChE degradation constant (time-1) 
Z1 = CaE synthesis rate (mass / time) 
Z2 = degradation constant (time-1) 
p1 = Acetylcholine binding rate (mass / time)  
p2 = Acetylcholine degradation constant (time-1) 
O1 = Oxime reaction rate coefficient for AChE (mass-1time-1) 
P1 = Oxime reaction rate coefficient for BuChE (mass-1time-1) 
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R1 = Oxime reaction rate coefficient for CaE (mass-1time-1) 
L1 = OP reaction rate coefficient with AChE (mass-1time-1) 
L2 = OP-AChE natural separation coefficient (time-1) 
L3 = OP-AChE aging coefficient (time-1) 
M1 = OP reaction rate coefficient with BuChE (mass-1time-1) 
M2 = OP-BuChE natural separation coefficient (time-1) 
M3 = OP-BuChE aging coefficient (time-1) 
N1 = OP reaction rate coefficient with CaE (mass-1time-1) 
N2 = OP-CaE natural separation coefficient (time-1) 
N3 = OP-CaE aging coefficient (time-1) 
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Appendix B. Parameters 
Physiological Parameters 
Body Weight    60.9 kg  Gearhart et. al.  
Cardiac Output   302 L/hr  Gearhart et. al. 
Pulmonary Rate   354 L/hr  Gearhart et. al. 
Blood Flow to Tissue Fractions 
 Arterial   1   Assumed 
 Brain    0.134   Gearhart et. al.  
 Diaphragm   0.006   Gearhart et. al. 
 Richly Perfused   0.2   Gearhart et. al.  
 Fat    0.036   Gearhart et. al.  
 Slowly Perfused   0.1244   Gearhart et. al.  
 Thigh    0.0066   Gearhart et. al.  
 Kidney   0.223   Gearhart et. al.  
Liver    0.27   Gearhart et. al. 
 Venous   1   Assumed 
Tissue Normalization Factors 
 Arterial   0.02 L/kg  Gearhart et. al. 
 Brain    0.0214 L/kg  Gearhart et. al. 
 Diaphragm   0.003 L/kg  Gearhart et. al.  
 Richly Perfused  0.0343 L/kg  Gearhart et. al. 
 Fat    0.17 L/kg  Gearhart et. al. 
 Slowly Perfused  0.5238 L/kg  Gearhart et. al. 
 Thigh    0.0276 L/kg  Gearhart et. al. 
 Kidney   0.0043 L/kg  Gearhart et. al. 
 Liver    0.04 L/kg  Gearhart et. al. 
 Venous   0.057 L/kg  Gearhart et. al. 
 
Organophosphate 
Molecular Weight   184 mg/mmol  Calculated 
Partition Coefficients 
 Brain    0.67   Gearhart et. al. 
 Diaphragm   0.77   Gearhart et. al. 
 RPT    0.67   Gearhart et. al. 
 Fat    17.6   Gearhart et. al. 
 SPT    0.77   Gearhart et. al. 
 Thigh    0.77   Gearhart et. al. 
 Kidney   1.63   Gearhart et. al. 
 Liver    1.53   Gearhart et. al. 
 Arterial   1   Assumed 
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 Venous   1   Assumed 
 Blood/Air   12.57   Gearhart et. al. 
Metabolic Parameters by A Esterases 
Brain Vmax   688 mg/hr  Gearhart et. al. 
Brain KM   440 mg/L  Gearhart et. al. 
RPT Vmax   560 mg/hr  Gearhart et. al. 
RPT KM   51 mg/L  Gearhart et. al. 
Kidney Vmax   5042 mg/hr  Gearhart et. al. 
Kidney KM   134 mg/L  Gearhart et. al. 
Liver Vmax   52474 mg/hr  Gearhart et. al. 
Liver KM   237 mg/L  Gearhart et. al. 
Venous Vmax   616 mg/hr  Gearhart et. al. 
Venous KM   199 mg/L  Gearhart et. al. 
Arterial Vmax   216 mg/hr  Gearhart et. al. 
Arterial KM   199 mg/L  Gearhart et. al. 
  
Oxime 
Molecular Weight   132 mg/mmol  Heath and McKeown 
Partition Coefficients 
 Brain    0.67   Assumed 
 Diaphragm   0.77   Assumed 
RPT    0.67   Assumed 
Fat    17.6   Assumed 
 SPT    0.77   Assumed 
 Thigh    0.77   Assumed 
 Kidney   1.63   Assumed 
 Liver    1.53   Assumed 
 Venous   1   Assumed 
 Arterial   1   Assumed  
 Blood/Air   0   Assumed 
Metabolic Parameters 
 Liver Vmax   52474 mg/hr  Assumed 
 Liver KM   237 mg/L  Assumed 
Kidney Partition Parameter 
 Elimination Partition  0.35   Assumed 
 
Atropine 
Molecular Weight   289 mg/mmol  Heath and McKeown 
Partition Coefficients 
 Bain    0.67   Assumed 
 Diaphragm   0.77   Assumed 
 RPT    0.67   Assumed 
 Fat    17.6   Assumed 
 SPT    0.77   Assumed 
 Thigh    0.77   Assumed 
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 Kidney   1.63   Assumed 
 Liver    1.53   Assumed 
 Venous   1   Assumed 
 Arterial   1   Assumed 
 Blood/Air   0   Assumed 
Metabolic Parameters 
 Liver Vmax   52474 mg/hr  Assumed 
 Liver KM   237 mg/L  Assumed 
Kidney Partition Parameter 
 Elimination Partition  0.35   Assumed 
 
Acetylcholinesterase 
Molecular Weight   320 mmol/mg  Assumed 
Synthesis Rate, X1 
 Arterial   0.0001 umol/hr Gentry et. al. 
 Brain    0.00002 umol/hr Scaled from Gentry et. al. 
 Diaphragm   0.000003 umol/hr Scaled from Gentry et. al.  
 RPT    0.00003 umol/hr Scaled from Gentry et. al. 
 Fat    0.0 umol/hr  Gentry et. al. 
 SPT    0.0005 umol/hr Scaled from Gentry et. al. 
 Thigh    0.00002 umol/hr Scaled from Gentry et. al. 
 Kidney   0.000004 umol/hr Scaled from Gentry et. al. 
 Liver    0.00004 umol/hr Scaled from Gentry et. al. 
 Venous   0.0001 umol/hr Gentry et. al.  
Initial Concentration 
Arterial   0.001212 umol Gentry et. al. 
 Brain    0.04928 umol  Gentry et. al. 
 Diaphragm   0.000909 umol Gentry et. al. 
 RPT    0.008314 umol Gentry et. al. 
 Fat    0.0 umol  Gentry et. al. 
 SPT    0.222196 umol Gentry et. al. 
 Thigh    0.011708 umol Gentry et. al. 
 Kidney   0.000104 umol Gentry et. al. 
 Liver    0.002424 umol Gentry et. al. 
 Venous   0.003454 umol Gentry et. al. 
Degradation Constant, X2 
Arterial   0.082508251 hr-1 Calculated 
 Brain    0.000405844 hr-1 Calculated 
 Diaphragm   0.00330033 hr-1 Calculated  
 RPT    0.003608371 hr-1 Calculated 
 Fat    0.0 hr-1  Calculated 
 SPT    0.002250266 hr-1 Calculated 
 Thigh    0.001708234 hr-1 Calculated 
 Kidney   0.038461538 hr-1 Calculated 
 Liver    0.01650165 hr-1 Calculated 
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 Venous   0.02895194 hr-1 Calculated 
 
Butyrylcholinesterase 
Molecular Weight   83.3 mmol/mg  Ashani and Pistinner 
Synthesis Rate, Y1 
 Arterial   0.0001 umol/hr Gentry et. al. 
 Brain    0.00002 umol/hr Scaled from Gentry et. al. 
 Diaphragm   0.000003 umol/hr Scaled from Gentry et. al.  
 RPT    0.00003 umol/hr Scaled from Gentry et. al. 
 Fat    0.0 umol/hr  Gentry et. al. 
 SPT    0.0005 umol/hr Scaled from Gentry et. al. 
 Thigh    0.00002 umol/hr Scaled from Gentry et. al. 
 Kidney   0.000004 umol/hr Scaled from Gentry et. al. 
 Liver    0.00004 umol/hr Scaled from Gentry et. al. 
 Venous   0.0001 umol/hr Gentry et. al.  
Initial Concentration 
Arterial   0.00606 umol  Gentry et. al. 
 Brain    0.016859 umol Gentry et. al. 
 Diaphragm   0.002 umol  Gentry et. al. 
 RPT    0.006236 umol Scaled from Gentry et. al. 
 Fat    0.0 umol  Gentry et. al. 
 SPT    0.190454 umol Gentry et. al. 
 Thigh    0.010035 umol Gentry et. al. 
 Kidney   0.000782 umol Gentry et. al. 
 Liver    0.019392 umol Gentry et. al. 
 Venous   0.017271 umol Gentry et. al. 
Degradation Constant, Y2 
Arterial   0.01650165 hr-1 Calculated 
 Brain    0.00118631 hr-1 Calculated 
 Diaphragm   0.0015 hr-1  Calculated  
 RPT    0.004810776 hr-1 Calculated 
 Fat    0.0 hr-1   Calculated 
 SPT    0.002625306 hr-1 Calculated 
 Thigh    0.001993034 hr-1 Calculated 
 Kidney   0.00511509 hr-1 Calculated 
 Liver    0.002062706 hr-1 Calculated 
 Venous   0.005790053 hr-1 Calculated 
 
Carboxylesterase 
Molecular Weight   320 mg/mmol  Assumed 
Synthesis Rate, Z1 
 Arterial   0.0001 umol/hr Gentry et. al. 
 Brain    0.00002 umol/hr Scaled from Gentry et. al. 
 Diaphragm   0.000003 umol/hr Scaled from Gentry et. al.  
 RPT    0.00003 umol/hr Scaled from Gentry et. al. 
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 Fat    0.0 umol/hr  Gentry et. al. 
 SPT    0.0005 umol/hr Scaled from Gentry et. al. 
 Thigh    0.00002 umol/hr Scaled from Gentry et. al. 
 Kidney   0.000004 umol/hr Scaled from Gentry et. al. 
 Liver    0.00004 umol/hr Scaled from Gentry et. al. 
 Venous   0.0001 umol/hr Gentry et. al.  
Initial Concentration 
Arterial   5.0904 umol  Gentry et. al. 
 Brain    0.778104 umol Gentry et. al. 
 Diaphragm   0.52722 umol  Gentry et. al. 
 RPT    442.73754 umol Scaled from Gentry et. al. 
 Fat    0.0 umol  Gentry et. al. 
 SPT    73.007244 umol Gentry et. al. 
 Thigh    3.846888 umol Gentry et. al. 
 Kidney   4.29957 umol  Gentry et. al. 
 Liver    110.292 umol  Gentry et. al. 
 Venous   14.50764 umol Gentry et. al. 
Degradation Constant, Z2 
Arterial   1.96448 * 10-5 hr-1 Calculated 
 Brain    2.57035 * 10-5 hr-1 Calculated 
 Diaphragm   5.69022 * 10-6 hr-1 Calculated  
 RPT    6.77602 * 10-8 hr-1 Calculated 
 Fat    0.0 hr-1  Calculated 
 SPT    6.848864 * 10-6 hr-1 Calculated 
 Thigh    5.19901 * 10-6 hr-1 Calculated 
 Kidney   9.30326 * 10-7 hr-1 Calculated 
 Liver    3.626674 * 10-7 hr-1 Calculated 
 Venous   6.89292 * 10-6 hr-1 Calculated 
 
Acetylcholine 
Molecular Weight   146 mg/mmol  about.com 
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Appendix C. Test Protocols and Results 
Table 3. Series A, B, and C Test Protocols 
Test No.  
Time-based dosing of antidotes 
1 2 mg of atropine and 600 mg of oximes every 5 minutes starting when symptoms equal to 
1.09 
2 2 mg of atropine every 5 minutes starting when symptoms equal to 1.09 
3 600 mg of oximes every 5 minutes starting when symptoms equal to 1.09 
Symptoms-based dosing of antidotes 
4 2 mg of atropine and 600 mg of oximes every time symptoms reach 1.09* 
5 2 mg of atropine every time symptoms reach 1.09* 
6 600 mg of oximes every time symptoms reach 1.09* 
Higher initial dose of antidotes; followed by time-based dosing of antidotes 
7 6 mg of atropine and 1800 mg of oximes when symptoms reach 1.09; additional 2 mg of 
atropine and 600 mg of oximes every 5 minutes 
8 6 mg of atropine when symptoms reach 1.09; additional 2 mg of atropine every 5 minutes 
9 1800 mg of oximes when symptoms reach 1.09; additional 600 mg of oxime every 5 minutes 
Higher initial dose of antidotes; followed by symptoms-based dosing of antidotes 
10 6 mg of atropine and 1800 mg of oximes when symptoms reach 1.09; additional 2 mg of 
atropine and 600 mg of oximes every time symptoms reach 1.09* 
11 6 mg of atropine when symptoms reach 1.09; additional 2 mg of atropine every time 
symptoms reach 1.09* 
12 1800 mg of oximes when symptoms reach 1.09; additional 600 mg of oximes every time 
symptoms reach 1.09* 
Pretreatment of antidotes by 5 minutes; followed by time-based doses of antidotes 
13 2 mg of atropine and 600 mg of oximes 5 minutes before organophosphate exposure begins 
and repeated every 5 minutes 
14 2 mg of atropine administered 5 minutes before organophosphate exposure begins and 
repeated every 5 minutes 
15 600 mg of oximes administered 5 minutes before organophosphate exposure begins and 
repeated every 5 minutes. 
Pretreatment of antidotes by 5 minutes; followed by symptoms-based doses of antidotes 
16 2 mg of atropine and 600 mg of oximes 5 minutes before organophosphate exposure begins 
and repeated every time symptoms reach 1.09* 
17 2 mg of atropine 5 minutes before organophosphate exposure begins and repeated every time 
symptoms reach 1.09* 
18 600 mg of oximes administered 5 minutes before organophosphate exposure begins and 
repeated every time symptoms reach 1.09* 
Control 
19 No administration of antidotes. 
*not to exceed injections more frequent than 5 minute intervals 
Reaction rate coefficients for Series A tests: L1 = 40,000; L2 = 100; L3 = 10,000; M1 = 80,000; M2 = 100; 
 M3 = 10,000; N1 = 20,000; N2 = 100; N3 = 10,000; O1 = P1 = R1 = 50 
Reaction rate coefficients for Series B and C tests: L1 = 20,000; L2 = 50; L3 = 20,000;  M1 = 40,000;  
M2 = 50; M3 = 20,000; N1 = 10,000; N2 = 50; N3 = 10,000; O1 = P1 = R1 = 100 
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Table 4. Series A Test Results 
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1 25.2 88.2 62 18576 31 31 8.4 0 114.0 102.0 0.43 Dec 
2 25.2 87.6 62 0 31 0 8.4 0 114.0 102.0 0.43 Dec 
3 25.2 45.6 0 18576 0 31 154.8 144.6 0 0 1.72 Inc 
4 25.2 N/A 4 1200 2 2 8.4 0 0 0 0.98 Dec 
5 25.2 N/A 4 0 2 0 0 0 0 0 0.98 Dec 
6 25.2 45.6 0 18576 0 31 0 144.6 0 0 1.72 Inc 
7 25.2 80.4 66 19776 31 31 144.6 0 121.8 109.2 0.41 Dec 
8 25.2 80.4 66 0 31 0 0 0 121.8 109.2 0.41 Dec 
9 25.2 45.6 0 19776 0 31 154.8 144.6 0 0 1.72 Inc 
10 25.2 108.0 6 18000 1 1 2.4 0 90.6 15.0 0.99 Inc 
11 25.2 108.0 6 0 1 0 2.4 0 90.6 15.0 0.99 Inc 
12 25.2 45.6 0 19776 0 31 154.8 144.6 0 0 1.72 Inc 
13 12.6 36.0 72 21600 36 36 0 0 167.4 154.2 0.33 Dec 
14 12.6 36.0 72 0 36 0 0 0 167.4 154.2 0.33 Dec 
15 25.8 45.6 0 21600 0 36 154.8 144.6 0 0 1.72 Inc 
16 92.4 N/A 4 1200 2 2 4.2 0 0 0 0.97 Inc 
17 94.4 N/A 4 0 2 0 4.2 0 0 0 0.97 Inc 
18 25.2 45.6 0 19200 0 32 154.8 144.6 0 0 1.72 Inc 
19 25.2 45.6 0 0 0 0 154.8 144.6 0 0 1.72 Inc 
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Table 5. Series B and C Test Results 
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1 37.8 80.4 56 16800 28 28 2.4 0 117.6 109.8 0.30 Dec 
2 37.8 80.4 56 0 28 0 2.4 0 117.6 109.8 0.30 Dec 
3 37.8 73.2 0 16800 0 28 142.2 117.0 0 0 1.31 Inc 
4 37.8 N/A 2 600 1 1 2.4 0 0 0 1.04 Inc 
5 37.8 N/A 2 0 1 0 2.4 0 0 0 1.04 Inc 
6 37.8 73.2 0 16800 0 28 142.2 117.0 0 0 1.31 Inc 
7 37.8 76.8 60 18000 28 28 1.2 0 113.4 113.4 0.28 Dec 
8 37.8 76.8 60 0 28 0 1.2 0 113.4 113.4 0.28 Dec 
9 37.8 72.6 0 18000 0 28 142.2 117.0 0 0 1.31 Inc 
10 37.8 73.2 6 18000 1 1 1.2 0 106.8 106.8 0.80 Inc 
11 37.8 83.4 6 0 1 0 1.2 0 106.8 106.8 0.80 Inc 
12 37.8 73.2 0 18000 0 28 142.2 117.0 0 0 1.31 Inc 
13 12.6 30.6 72 21600 36 36 0 0 167.4 159.6 0.21 Dec 
14 12.6 30.6 72 0 36 0 0 0 167.4 159.6 0.21 Dec 
15 37.8 73.2 0 21600 0 36 142.2 117.0 0 0 1.31 Inc 
16 14.4 N/A 4 1200 2 2 1.2 0 81.6 0 1.06 Dec 
17 14.4 N/A 4 0 2 0 1.8 0 81.6 0 1.06 Dec 
18 37.8 73.2 0 17400 0 28 142.2 117.0 0 0 1.31 Inc 
19 37.8 73.2 0 0 0 0 136.2 117.0 0 0 1.31 Inc 
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Table 6. Series D and E Test Protocol 
Test No. L1 L2 L3 O1 Oxime Dose 
1 20000 50 20000 100 No dose 
2 20000 50 20000 100 600 mg of oxime every 5 min starting at time 0 and ending 
after 30 min 
3 20000 50 20000 500 No dose 
4 20000 50 20000 500 600 mg of oxime every 5 min starting at time 0 and ending 
after 30 min 
5 20000 50 5000 100 No dose 
6 20000 50 5000 100 600 mg of oxime every 5 min starting at time 0 and ending 
after 30 min 
7 5000 50 5000 7000 No dose 
8 5000 50 5000 7000 2 doses of 600 mg of oxime at time 0 and at time 5 min 
9 20000 50 100 2500 No dose 
10 20000 50 100 2500 2 doses of 600 mg of oxime at time 0 and at time 5 min 
M1 = 2 * L1 
N1 = 0.5 * L1 
L2 = M2 = N2 
O1 = P1 = R1 
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Table 7. Series D Test Results 
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1 37.8 73.2 0 0 142.2 117 1.31 Inc 0.011677 26.4 
2 37.8 73.2 3600 6 142.2 117 1.31 Inc 0.011678 29.4 
3 37.8 73.2 0 0 142.2 117 1.31 Inc 0.011677 26.4 
4 37.8 73.8 3600 6 142.2 116.4 1.30 Inc 0.011686 26.4 
5 37.8 73.8 0 0 142.2 117.6 1.30 Inc 0.011696 27.0 
6 37.8 73.8 3600 6 142.2 117.6 1.30 Inc 0.011703 27.0 
7 N/A N/A 0 0 0 0 1.09 Inc 0.014369 27.6 
8 N/A N/A 1200 2 0 0 1.08 Inc 0.014484 25.8 
9 48.0 103.2 0 0 132 87 1.22 Inc 0.012662 27.0 
10 154.2 N/A 1200 2 25.8 0 1.09 Inc 0.014307 27.0 
 
 
Table 8. Series E Test Results 
Te
st
 N
o.
 
Fi
rs
t a
pp
ea
ra
nc
e 
of
 
sy
m
pt
om
s (
m
in
) 
Ti
m
e 
at
 d
ea
th
 (m
in
) 
To
ta
l a
m
ou
nt
 o
f 
ox
im
es
 (m
g)
 
N
o.
 o
f o
xi
m
e 
in
je
ct
io
ns
 
To
ta
l t
im
e 
sy
m
pt
om
s >
 
1.
09
 (m
in
) 
To
ta
l t
im
e 
sy
m
pt
om
s >
 
1.
16
 (m
in
) 
Sy
m
pt
om
 le
ve
ls
 a
t 3
 
ho
ur
s 
Sy
m
pt
om
s t
re
nd
 a
t 3
 
ho
ur
s 
M
in
 A
C
hE
 le
ve
ls
 (m
g)
 
Ti
m
e 
at
 m
in
 A
C
hE
 
le
ve
ls
 (m
in
) 
1 37.8 73.2 0 0 142.2 117 1.31 Inc 0.011677 26.4 
2 37.8 73.2 3600 6 142.2 117 1.31 Inc 0.011678 28.8 
3 37.8 73.2 0 0 142.2 117 1.31 Inc 0.011677 26.4 
4 37.8 73.8 3600 6 142.2 116.4 1.30 Inc 0.011683 27.0 
5 37.8 73.8 0 0 142.2 116.4 1.30 Inc 0.011690 27.0 
6 37.8 73.8 3600 6 142.2 116.4 1.30 Inc 0.011701 27.0 
7 N/A N/A 0 0 0 0 1.09 Inc 0.014369 27.6 
8 N/A N/A 1200 2 0 0 1.08 Inc 0.014474 26.4 
9 48.0 103.2 0 0 132.0 87.0 1.22 Inc 0.012662 27.0 
10 102.6 N/A 1200 2 77.4 0 1.11 Inc 0.014044 25.8 
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Table 9. Series F Test Protocol 
 Fast OP reaction  Slow OP reaction 
Fast aging 10 minute aging half-life 
L1 = 1000000 
L3 = 4.5 
Tests 1-3, 19-21 
10 minute aging half-life 
L1 = 50000 
L3 = 4.5 
Tests 4-6, 22-24 
Moderate aging 5 hour aging half-life 
L1 = 1000000 
L3 = 0.16 
Tests 7-9, 25-27 
5 hour aging half-life 
L1 = 50000 
L3 = 0.16 
Tests 10-12, 28-30 
Slow aging 48 hour aging half-life 
L1 = 1000000 
L3 = 0.014 
Tests 13-15, 31-33 
48 our aging half-life 
L1 =50000 
L3 = 0.014 
Tests 16-18, 34-36 
Each scenario consisted of 3 tests. For the first test, no oxime administration. For the second tests, 600 mg 
of oxime repeated every 5 minutes, starting at noticeable symptoms. For the third test, 600 mg of 
 oxime repeated every 5 minutes, starting at time 0. 
Tests 1 through 18 used an exposure of 5 mg of OP for 15 minutes starting at time +5 minutes 
Tests 19 through 36 used an exposure of 10 mg of OP for 20 minutes starting at time +5 minutes 
Oxime reaction rate coefficient set equal to 20 
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Table 10. Series F Test Results 
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1 26.4 0.76 0 0 153.6 144.6 1.78 Inc 0.007683 0.007691 
2 26.4 0.76 18000 30 153.6 144.6 1.87 Inc 0.007007 0.007031 
3 25.8 0.73 21600 36 154.2 146.4 1.99 Inc 0.006309 0.006375 
4 27.6 0.83 0 0 152.4 140.4 1.57 Inc 0.009209 0.009216 
5 26.0 0.83 18000 30 152.4 140.4 1.53 Inc 0.009209 0.009607 
6 29.4 0.94 21600 36 150.6 133.8 1.39 Inc 0.009888 0.010821 
7 26.4 0.76 0 0 153.6 144.6 1.78 Inc 0.007683 0.007691 
8 26.4 0.76 18000 30 153.6 147.6 1.71 Dec 0.005543 0.010338 
9 25.2 0.71 21600 36 154.8 147.6 1.59 Dec 0.005585 0.011114 
10 27.6 0.83 0 0 152.4 130.2 1.57 Inc 0.009209 0.009216 
11 27.6 0.85 18000 30 152.4 70.8 1.09 Dec 0.009209 0.014967 
12 30.6 N/A 21600 36 70.8 0 1.05 Dec 0.010160 0.015298 
13 26.4 0.76 0 0 2.56 144.6 1.78 Inc 0.007683 0.007691 
14 26.4 0.76 18000 30 153.6 144.6 1.65 Dec 0.005497 0.011356 
15 25.2 0.71 21600 36 153.6 147.6 1.53 Dec 0.005563 0.012229 
16 27.6 0.83 0 0 152.4 140.4 1.57 Inc 0.009209 0.009216 
17 27.6 0.85 13200 22 111.0 57.6 1.05 Dec 0.009209 0.015695 
18 30.6 N/A 21600 36 58.2 0 1.02 Dec 0.010172 0.015727 
19 18.0 32.4 0 0 162.0 157.8 3.79 Inc 0.000001 0.000016 
20 18.0 32.4 19200 32 162.0 157.8 3.38 Inc 0.000040 0.001126 
21 18.0 32.4 21600 36 162.0 157.8 3.28 Inc 0.001334 0.001411 
22 21.0 36.6 0 0 159.0 153.6 2.76 Inc 0.002929 0.002941 
23 21.0 36.6 18000 30 159.0 153.6 2.38 Inc 0.003193 0.004518 
24 21.6 37.8 21600 36 158.4 152.4 2.03 Inc 0.004586 0.006272 
25 18.0 32.4 0 0 162.0 157.8 3.79 Inc 0.000001 0.000016 
26 18.0 32.4 19200 32 162.0 157.8 1.88 Dec 0.000058 0.010069 
27 18.0 32.4 21600 36 162.0 157.8 1.79 Dec 0.003070 0.010504 
28 21.0 36.6 0 0 159.0 153.6 2.76 Inc 0.002929 0.002941 
29 21.0 36.6 18000 30 159.0 151.8 1.16 Dec 0.003374 0.014468 
30 21.6 0.65 21600 36 158.4 88.2 1.10 Dec 0.005547 0.014876 
31 18.0 39.0 0 0 162.0 157.8 3.79 Inc 0.000001 0.000016 
32 18.0 32.4 19200 32 162.0 157.8 1.76 Dec 0.000058 0.011536 
33 18.0 32.4 21600 36 162.0 157.8 1.67 Dec 0.003158 0.011970 
34 21.0 36.6 0 0 159.0 153.6 2.76 Inc 0.002929 0.002941 
35 21.0 36.6 18000 30 151.8 109.2 1.08 Dec 0.003382 0.015650 
36 21.6 39.0 21600 36 114.6 70.2 1.05 Dec 0.005593 0.015689 
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